Identification of activated receptors and ion channels

ABSTRACT

The present invention related to methods and reagents for generating and using activating mutations of receptors and ion channels.

REFERENCE TO RELATED APPLICATIONS

This is a continuation of U.S. patent application Ser. No. 09/943,641,filed Aug. 30, 2001, which is co-pending, which claims priority toProvisional application 60/229,243, filed on Aug. 30, 2000, the contentsof which are incorporated herein by reference in their entirety.

BACKGROUND OF THE INVENTION

The search for agonists and antagonists of cellular receptors has beenan intense area of research aimed at drug discovery due to the elegantspecificity of these molecular targets. Being able to generateactivating mutations in a receptor can be useful in many different ways.For instance, the superfamily of G-protein coupled receptors (GPCRs)represents one of the most important families of drug targets for thepharmaceutical industry. They are activated by a wide range ofextracellular signals including small biogenic amines, large proteinhormones, neuropeptides, chemokines, lipid-derived mediators and evenproteases such as thrombin. They are also fundamental receptors for thesensory perception of light, taste and smell. Moreover, of the top 200best selling prescription drugs, more than 20% interact with GPCRs,providing worldwide sales of over $20 billion.

GPCRs transduce their signals across the plasma membrane via aninteraction with heterotrimeric G-proteins, and this leads to anactivation of intracellular effectors such as adenylate cyclase orphospholipase C and subsequent generation of second messengers such ascAMP (cyclic adenosine-monophosphate) or calcium. These effects areamplified and transmitted down through a cascade of intracellular eventsleading eventually to the physiological response of the cell to thestimulus. The enormous diversity of receptors, G-proteins and effectors,together with the widespread distribution of receptors across manytissues, reflects the important role that this family of genes plays inregulating physiological and pathophysiological processes.

The characteristic “motif of the GPCR family are the 7 distincthydrophobic regions, each 20 to 30 amino acids in length, generallyregarded as forming the transmembrane domains of these integral membraneproteins. Indeed, the alternative name for this family is that of “7TMreceptors.” There is little conservation of amino acid sequence acrossthe entire superfamily of receptors, but key sequence motifs can befound within phylogenetically related subfamilies, and these motifs canbe used to help classify new members.

Since the first cloning of a GPCR more than a decade ago, over athousand members of the family have been cloned from a variety ofdifferent species. This includes more than 160 distinct sub-types ofhuman receptor for which the natural ligand is known, as well as over100 human-derived receptor sequences for which the cognate ligandremains to be identified. The sequence motifs exhibited by these“orphan” receptors places them firmly in the GPCR family, but theytypically show very low sequence similarity to specific known receptors,generally less than 40%. They are distributed throughout the GPCRphylogenetic tree, and many show better sequence similarity to eachother than to known GPCRs, suggesting that they may represent newsubfamilies of receptors with distinct, possibly novel, ligands. Themajority of orphan receptors have been derived as a result oflarge-scale DNA sequencing, and as the generation of genomic informationcontinues to increase, so the number of orphan receptors identified insequence databases continues to increase. There is considerable debateconcerning the total number of GPCRs that exist in the human genome, andestimates vary widely from 400 up to 5000. According to the first draftof the entire human genome published as part of the Human GenomeProject, there are 616 human GPCRs if only rhodopsin-class,secretin-class, and metabotropic glutamate-class GPCRs are included (J.Craig Venter et al., Table 19 in Science 291: 1304-51).

Indeed, the current human genome sequencing efforts are identifying vastnumbers of DNA sequences that may encode receptors, in general, forwhich corresponding ligands have not yet been identified. In somecircumstances, the physiological events in which these orphan receptorsare involved are not yet known either, and reagents for elucidating thereceptor's physiological function is of importance. In other instances,the receptor is known to play an important physiological role andthereby could provide a means for developing therapeutics for diseasesin which these receptors play a role.

The overall strategy for characterizing orphan receptors is oftenreferred to as a “reverse pharmacology” approach to distinguish if frommore conventional drug discovery approaches. The conventional approachwas historically initiated by the discovery of a biological activity forwhich the ligand responsible was identified and then used tocharacterize tissue pharmacology and physiological role. Subsequently,the ligand was used to clone its corresponding receptor for use as adrug target in high-throughput screening. The reverse approach startswith an orphan receptor of unknown function that is used as a “hook” tofish out its ligand. The ligand is then used to explore the biologicaland pathophysiological role of the receptor. High-throughput screeningis initiated on the receptor in parallel with the biologicalcharacterization in order to develop antagonists that will helpdetermine the therapeutic value of the receptor.

One of the many great challenges in biology and medicine is to decipherthe function of orphan receptors and their mechanism of action. However,traditional efforts to identify ligands for orphan receptors can beinefficient because they involve, methodical searches through likelytissue sources to identify the natural ligand for the orphan receptor ofinterest. There is currently a need to be able to activate a receptorwithout knowledge of its ligand in order to mimic the effects of ligandbinding. Such activated systems can be used to develop functionalcell-based and biochemical assays, e.g., for drug screening, as well asto better understand the signal transduction process into which receptorintegrates.

Another aspect of receptor-mediated signaling is that constitutivelyactivating mutations have been identified in members of virtually everyreceptor family. Moreover, such activating mutations have beenimplicated in a variety of pathological conditions.

To further illustrate, constitutively active G protein-coupled receptors(GPCRs) were first identified in chimeras of the ocj- and P2-adrenergicreceptors. Ultimately, this effect was mapped to residues at theC-terminal end of the third intracellular loop, and, in particular, thereplacement of an alanine at position 293 with any other residue wasfound to increase the basal activity of the receptor and enhance theaffinity for ligand as much as 100 fold. After the identification ofnaturally occurring constitutively active MCl-Rs and rhodopsinmolecules, activating mutations in GPCRs were found to be responsiblefor a diverse array of inherited as well as somatic genetic disordersincluding hyperfunctioning thyroid adenomas, autosomal dominanthyperthyroidism, familial precocious male puberty, mettaphysealchondrodysplasia, familial hypoparathyroidism, and congenital nightblindness.

While constitutively activating mutations have been found in virtuallyall domains of the GPCRs, some mechanistic similarities are commonlyfound. Many constitutively active receptors demonstrate a higheraffinity for agonist and lower EC50 for further activation. In somecases the increased affinity for agonist, but not antagonist, wasdramatic, and the correlation between agonist efficacy and increasedaffinity in the constitutively active mutants led to a proposedmodification of the ternary complex model for GPCR activation. Theestablished model holds that agonist binding stabilizes the activeconformation (R*G) of the receptor in a complex with G protein whileantagonists typically bind equally well to R and R*. Based on theidentification and characterization of constitutively active GPCRs, anextended or allosteric ternary complex model was proposed in whichreceptor, independent of ligand binding, is in equilibrium between aninactive and active conformation. Mutations that constitutively activatereceptors are proposed to disrupt internal constraints in the receptors,make the receptors less conformationally constrained, and thereforedecrease the energy required to reach the R* state. The model thusexplains the increased affinity of agonists for constitutively activereceptors, even in the absence of G protein, since constitutiveactivation results in a higher percentage of receptors in thehigh-affinity R* state.

Because of the prevalence of constitutively active mutants of GPCRs andother extracellular receptors, there is currently a need to be able toactivate a receptor without knowledge of its ligand in order to studythe mechanism of action by which activating mutants give rise to diseasestates.

SUMMARY OF THE INVENTION

The present invention makes available a rapid, effective assay forscreening and identifying mutations in receptors or ion channels,especially cell surface receptors and ion channels, which give rise toconstitutively activated signaling. The subject assay enable rapidgeneration and identification of such activating mutations (point ormultiple mutations), e.g., by combinatorial or scanning mutagenesis atresidues which are most likely to contribute to conformational changesin the mutant receptor that result in activation.

Moreover, the subject activated receptors and ion channels can be usedto generate drug screening assays for testing agents for their abilityto overcome the effects of the activating mutations, e.g., to identifypotential antagonists of the mutated, and in some instances, wild-typereceptor or ion channel. Such assays enable rapid screening of largenumbers of compounds to identify those which antagonize receptorbioactivity. Moreover, understanding the signaling events downstream ofan orphan receptor, e.g., to identify second messengers andtranscriptional targets for use as reporters to detect activation ofthe—receptor, can permit the design of assays using wild-type receptorand for identifying agonists.

One aspect of the invention provides a method for identifyingconstitutively activating mutations in a receptor or an ion channel,comprising:

-   -   (A) providing a library of coding sequences for potentially        activating mutations of a candidate receptor or ion channel,        which library is generated by replacing coding sequences for        small or medium side-chain amino acids with coding sequences for        large side-chain amino acids, wherein said small or medium        side-chain amino acids are located in or proximate transmembrane        segment(s) of the receptor or ion channel;    -   (B) expressing said library in host cells;    -   (C) measuring the activity of the encoded receptor or ion        channels in said host cells;    -   (D) identifying those coding sequence(s) which encoded activated        receptors or ion channels.

In one embodiment, the receptor is selected from the group consistingof: a growth factor receptor, a cytokine receptor, a chemokine receptor,and an multisubunit immune recognition receptor (MIRR). In a relatedembodiment, the receptor is an orphan receptor. In another relatedembodiment, the receptor is a receptor tyrosine kinase (RTK). In anotherrelated embodiment, the receptor is a multipass transmembrane receptor.More preferably, the multipass transmembrane receptor is a 7TM receptorselected from the group consisting of: a G-protein coupled receptor, achemoattractant peptide receptor, a neuropeptide receptor, a lightreceptor, a neurotransmitter receptor, and a polypeptide hormonereceptor. In another related embodiment, the ion channel is a ligandgated ion channel.

In one embodiment, the activity of the receptor or ion channel ismeasured directly by determining the level of second messengersgenerated in response to receptor or ion channel activation. In arelated embodiment, the activity is measured indirectly via an indicatorgene. The indicator gene can be an unmodified endogenous gene. Theindicator gene can also be a heterologous reporter gene, the activationof the transcriptional regulatory element of which is directly orindirectly regulated by the receptor or ion channel. In one embodiment,the level of transcriptional activation of the indicator gene can beamplified by overexpressing one or more intermediate components of thesignaling cascade leading to the activation of the indicator gene. Inanother embodiment, the sensitivity of the indicator gene is modified bymanipulating the promoter sequence at the natural locus for theindicator gene. In another embodiment, the activity of the indicatorgene is modified by manipulating the transcriptional regulatory sequenceat the natural locus for the indicator gene. In another embodiment, theactivity of the indicator gene is modified by replacing thetranscriptional regulatory sequence of the endogenous indicator genewith that of a heterologous gene. In one embodiment, the transcriptionalregulatory element is derived from that of immediate early genes. Inanother embodiment, the transcriptional regulatory element is derivedfrom several heterologous genes. In one embodiment, the reporter geneencodes a gene product selected from the group consisting of:chloramphenicol acetyl transferase, beta-galactosidase, secretedalkaline phosphatase, a gene product which confers a growth signal, anda gene product for growth in media containing aminotriazole orcanavanine.

In one embodiment, the small or medium side-chain amino acids arelocated at the interfaces between transmembrane helices. In anotherembodiment, the small or medium side-chain amino acids are selected fromthe group consisting of: glycine, alanine, and serine. In yet anotherembodiment, the small or medium side-chain amino acids are selected fromthe group consisting of: asparagine, aspartic acid, cysteine, proline,threonine and valine. In one embodiment, the large/bulky side-chainamino acids are selected from the group consisting of: tryptophane,leucine, histidine, threonine, and tyrosine. In another embodiment, thelarge side-chain amino acids are selected from the group consisting of:asparagine, cysteine, glutamine, isoleucine, methionine, phenylalanine,proline, and valine.

In one embodiment, the cell is a prokaryotic cell. In anotherembodiment, the cell is a eukaryotic cell. More preferably, theeukaryotic cell is a mammalian cell. In another embodiment, the cell isselected from the group consisting of: an avian cell, an insect cell, ayeast cell, and a plant cell. In a preferred embodiment, the cell is apigment cell capable of dispersing or aggregating its pigment inresponse to an activated receptor or ion channel.

In one embodiment, the mutation is identified as an activating mutationif the activity of the mutant polypeptide increases by at least 2-fold,preferably 5-fold, 10-fold or even more when compared to the activity ofthe wild-type polypeptide.

Another aspect of the invention provides a method for identifyingconstitutively activating mutations in a multipass transmembranereceptor, comprising:

-   -   (A) providing a library of coding sequences for a multipass        transmembrane receptor, which library includes variant sequences        which differ from the wild-type sequence of the receptor by one        or more point mutations in or proximate a transmembrane        segment(s) of the receptor that replace a small or medium amino        acid residue with a large amino acid residue;    -   (B) expressing said library in host cells;    -   (C) measuring the activity of the encoded multipass        transmembrane receptor in said host cells;    -   (d) identifying those coding sequence(s) which encoded activated        multipass transmembrane receptor.

Another aspect of the invention provides a method for identifying atarget second messenger or downstream signaling component of a receptoror ion channel, comprising:

-   -   (A) identifying an activating mutation of a receptor or ion        channel using the method of claim 1;    -   (B) expressing said activating mutation of a receptor or ion        channel in host cells; and,    -   (C) identifying one or more second messenger molecules or        downstream signaling components whose level is higher or lower        or which is modified as a consequence to expression of said        activating mutation of said receptor or ion channel.

In one embodiment, the receptor is selected from the group consistingof: a growth factor receptor, a cytokine receptor, a chemokine receptor,and an multisubunit immune recognition receptor (MIRR). In anotherembodiment, the receptor is a multipass transmembrane receptor. In apreferred embodiment, the multipass transmembrane receptor is a 7TMreceptor selected from the group consisting of: a G-protein coupledreceptor, a chemoattractant peptide receptor, a neuropeptide receptor, alight receptor, a neurotransmitter receptor, and a polypeptide hormonereceptor. In yet another embodiment, the receptor is a receptor tyrosinekinase (RTK).

Another aspect of the invention provides a method for identifying anantagonist of an activating mutation of a receptor or ion channel,comprising:

-   -   (A) translationally providing a constitutively active mutant of        a receptor or ion channel in an environment, which active mutant        includes one or more point mutation(s) in or proximate a        transmembrane segment(s) of the receptor that replace a small or        medium amino acid residue with a large amino acid residue;    -   (B) contacting the receptor or ion channel with a test agent;    -   (C) comparing the activity of the receptor or ion channel in the        presence of the test agent with the activity of the receptor or        ion channel in the absence of the test agent; and,    -   (D) identifying the test agent as an antagonist of the activated        receptor or ion channel if the activity of the receptor or ion        channel in the presence of the test agent is lower than the        activity of the receptor or ion channel in the absence of the        test agent.

In one embodiment, the translationally providing step is performed in acell. The cell can be a prokaryotic cell, or a eukaryotic cell. Inanother embodiment, the cell is selected from the group consisting of: amammalian cell, an avian cell, an insect cell, a yeast cell, and a plantcell. In a preferred embodiment, the cell is a pigment cell capable ofdispersing or aggregating its pigment in response to an activatedreceptor or ion channel.

In one embodiment, the test agent is a member of a library. The librarycan be selected from the group consisting of: a randomly synthesizedpolypeptide library, a semi-randomly synthesized polypeptide library, acDNA encoded polypeptide library, a genomic DNA encoded polypeptidelibrary, a synthetic chemical library, and a natural chemical compoundlibrary.

Another aspect of the present invention relates to the generation oftransgenic animals, preferably non-human mammals, expressing theactivated mutants discovered by the subject method. Such animals can beused, merely for illustration, as disease models to elucidate theetiology and pathology of a disorder, as well as to test potentialantagonists or other therapeutic agents in vivo.

This aspect of the invention provides a method for generating anon-human transgenic animal which expresses at least one activatingmutant(s) of a receptor or an ion channel, comprising the steps of: (A)identifying an activating mutant of a receptor or an ion channel usingthe method of claim 1; and, (B) generating a non-human transgenic animalexpressing said activating mutant. In one embodiment, the transgenicanimal is selected from the group consisting of: a mammal, an insect,and a yeast.

Another aspect of the invention provides a method for identifying amodulator of a receptor or ion channel, comprising:

-   -   (A) identifying an activating mutation of a receptor or ion        channel using the method of claim 1;    -   (B) identifying one or more second messenger molecules or        downstream signaling components whose level is higher or lower        or which is modified as a consequence to expression of said        activating mutation of said receptor or ion channel;    -   (C) contacting an environment expressing a wild-type receptor or        ion channel with a test agent;    -   (D) comparing the level of target second messenger molecules or        down stream signaling components identified in step (B) in the        presence or absence of the test agent; and,    -   (E) determining whether the test agent increases or decreases        the level of the target second messenger.

Another aspect of the invention provides a method of conducting apharmaceutical business, comprising:

-   -   (A) by the method of claim 38 or 48, identifying one or more        agents which effects signaling by a cell-surface receptor or ion        channel;    -   (B) conducting therapeutic profiling of said identified        agent(s), or further analogs thereof, for efficacy and toxicity        in animals; and,    -   (C) formulating a pharmaceutical preparation including one or        more agents identified in step (B) as having an acceptable        therapeutic profile.

In one embodiment, the business method further comprises an additionalstep of establishing a distribution system for distributing thepharmaceutical preparation for sale. In a preferred embodiment, thebusiness method further includes establishing a sales group formarketing the pharmaceutical preparation.

Another aspect of the invention provides a method of conducting apharmaceutical business, comprising:

-   -   (A) by the method of claim 38 or 48, identifying one or more        agents which effects signaling by a cell-surface receptor or ion        channel;    -   (B) (optionally) conducting therapeutic profiling of the agent        for efficacy and toxicity in animals; and,    -   (C) licensing, to a third party, the rights for further drug        development of the target agent.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1. Two state description of seven transmembrane receptor function.In an unstimulated state (1) the receptor exists in equilibrium betweenactive (R*) and inactive (R) states. (2) Agonist (A) binds specificallyto the active state (R*) and through mass action activates the receptorby increasing the total concentration of activated receptor([R*]+[R*A]). (3) Inverse agonist inactivates receptor analogously bybinding specifically to the inactive state. (4) Mutation (Ra) activatesthe receptor by affecting the two-state equilibrium to increase thefraction of receptor in the active state. (5) Inverse agonist caninactivate activated receptor by mass action. (6) Downstream couplinginhibitor (D) inhibits receptor signaling by binding to receptor andinhibiting activation of downstream targets.

FIG. 2. Identification of Smoothened activating mutations at twoglycines identified by the subject screening method. Activities ofaltered proteins are normalized to a value of 1 for wild-typeSmoothened.

DETAILED DESCRIPTION OF THE INVENTION I. Overview

Proliferation, differentiation and death of eukaryotic cells arecontrolled by a variety of extracellular signals, such as hormones,neurotransmitters, and polypeptide factors. These diffusible ligandsallow cells to influence and be influenced by environmental cues. Thestudy of receptor activation has revealed a great deal of informationabout how cells respond to external stimuli, and this knowledge has ledto the development of therapeutically important compounds.

The present invention makes available a rapid, effective assay forscreening and identifying mutations in receptors or ion channels,especially cell surface receptors, which give rise to constitutivelyactivated signaling. The subject assay enables rapid generation andidentification of such activating mutations (point or multiplemutations), e.g., by combinatorial or scanning mutagenesis at residueswhich are most likely to contribute to conformational changes in themutant receptor that result in activation. That is, in the case of 7TMreceptors, the mutagenic approach is expected to give rise to forms ofthe receptor in which the steady-state equilibrium of the receptor isshifted towards the active form (R*) relative to the wild-type receptor.

To illustrate, seven transmembrane (7TM) receptors are thought to existin two conformational states, active and inactive. In unstimulatedcells, these states are in an equilibrium that strongly favors theinactive state (see FIG. 1). Agonists bind specifically to the activeconformation of the receptor, increasing its concentration by massaction. Mutations exist that constitutively activate these receptors bydestabilizing the inactive state, or by increasing the stability of theactive state.

The present invention provides a systematic method of activating 7TM andother classes of cell surface receptors and ion channels. The strategyis based on systematically changing small residues (glycines, alaninesand serines) found in transmembrane segments to larger residues. Thesesmall residues are preferred at the interfaces between transmembranehelices, e.g., be they intramolecular interactions such as in the caseof multi-pass receptors and ions channels, or intermolecularinteractions such as in the case of single pass receptors. Mostmutations at these small residues will introduce side-chains that aresubstantially larger. These larger side-chains will then force theprotein to adopt a different conformation, or prevent interaction withanother molecule (e.g., a ligand or receptor subunit). The strategyinvolves generation of a set of libraries of mutant proteins where smallresidues at defined positions are changed to a number of other morebulky amino acid residues. The resulting library of mutants can betested individually or in pools in biological assays to determine whichsubstitutions induce constitutive activity. To illustrate, the librarycan be transfected into a host cell, and the activation of downstreamsecond messengers or transcriptional targets thereof (reporter genes)can be detected.

Initial application of the subject method to four glycines in Smoothenedhas yielded eight activating mutants at two different sites (see FIG.2). Our results indicate that this strategy may be used for rapidgeneration of activated forms of a large number of 7TM receptors, andsuggests that the method can be applied to residues in the transmembraneregions of other classes of receptors and ion channels. In certainpreferred embodiments, the receptor protein can be any receptor or ionchannel which interacts with an extracellular molecule (i.e. hormone,growth factor, peptide, ion) to modulate a signal in the cell. Inpreferred embodiments, the receptor is a cell surface receptor, such as:a receptor tyrosine kinase, e.g., an EPH receptor; an ion channel; acytokine receptor; an multisubunit immune recognition receptor, achemokine receptor; a growth factor receptor, a 7TM receptor (such as aG-protein coupled receptor, e.g., a chemoattractant peptide receptor, aneuropeptide receptor, a light receptor, a neurotransmitter receptor, ora polypeptide hormone receptor), a multipass transmembrane receptor.

Preferred G protein coupled receptors include cd A-adrenergic receptor,a1B-adrenergic receptor, a2-adrenergic receptor, a2B-adrenergicreceptor, pi-adrenergic receptor, (32-adrenergic receptor, p3-adrenergicreceptor, m1 acetylcholine receptor (AChR), m2 AChR, m3 AChR, m4 AChR,m5 AChR, D1 dopamine receptor, D2 dopamine receptor, D3 dopaminereceptor, D4 dopamine receptor, D5 dopamine receptor, A1 adenosinereceptor, A2b adenosine receptor, 5-HT1a receptor, 5-HTIb receptor,5HT1-like receptor, 5-HTId receptor, 5HT1d-like receptor, 5HT1d betareceptor, substance K (neurokinin A) receptor, fMLP receptor, fMLP-likereceptor, angiotensin II type 1 receptor, endothelin ETA receptor,endothelin ET13 receptor, thrombin receptor, growth hormone-releasinghormone (GHRH) receptor, vasoactive intestinal peptide receptor,oxytocin receptor, somatostatin SSTR1 and SSTR2, SSTR3, cannabinoidreceptor, follicle stimulating hormone (FSH) receptor, leutropin(LH/HCG) receptor, thyroid stimulating hormone (TSH) receptor,thromboxane A2 receptor, platelet-activating factor (PAF) receptor, C5aanaphylatoxin receptor, Interleukin 8 (IL-8) IL-8RA, IL-8RB, DeltaOpioid receptor, Kappa Opioid receptor, mip-1/RANTES receptor,Rhodopsin, Red opsin, Green opsin, Blue opsin, metabotropic glutamatemGluR1-6, histamine H2 receptor, ATP receptor, neuropeptide Y receptor,amyloid protein precursor receptor, insulin-like growth factor IIreceptor, bradykinin receptor, gonadotropin-releasing hormone receptor,cholecystokinin receptor, prostaglandin receptor, melanocyte stimulatinghormone receptor, antidiuretic hormone receptor, glucagon receptor, andadrenocorticotropic hormone II receptor.

The subject method is particularly well suited for analysis oftransmembrane proteins whose biological function is gated byconformational changes (such as ligand gated ion channels). Accordingly,it is specifically contemplated that particularly preferred embodimentsare where the receptor is a multipass transmembrane protein.

Moreover, the subject activated receptors and ion channels can be usedto generate drug screening assays for testing agents for their abilityto overcome the effects of the activating mutations, e.g., to identifypotential antagonists of the mutated, and in some instances, wild-typereceptor or ion channel. Such assays enable rapid screening of largenumbers of compounds to identify compounds which antagonize receptorbioactivity. Moreover, understanding the signaling events downstream ofan orphan receptor, e.g., to identify second messengers andtranscriptional targets for use as reporters to detect activation of thereceptor, can permit the design of assays using wild-type receptor andfor identifying agonists.

Another aspect of the present invention relates to the generation oftransgenic animals, preferably non-human mammals, expressing theactivated mutants discovered by the subject method. Such animals can beused, merely for illustration, as disease models to elucidate theetiology and pathology of a disorder, as well as to test potentialantagonists or other therapeutic agents in vivo.

II. Definitions

Before further description of the invention, certain terms employed inthe specification, examples and appended claims are, for convenience,collected here.

“Activated,” “activating” or “active” as used herein all refers toincreased activity (biological, biochemical, etc.) as compared towild-type. Generally, an activated receptor or ion channel exhibits astatistically significant increase of at least 10%, preferably 20%, 50%,100%, 2-fold, 5-fold, 10-fold or more in activity when compared to itswild-type counterparts under certain assay conditions. The activity of aparticular receptor or ion channel can be measured using any one or acombination of methods as outlined below.

“Agonists” and “antagonists” are molecules that modulate signaltransduction via a receptor or ion channel. Agonists and one class ofantagonists are capable of binding to the receptor, though notnecessarily at the binding site of the natural ligand, and can modulatesignal transduction when used alone (i.e. can be surrogate ligands, orcan alter signal transduction in the presence of the natural ligand,either to enhance or inhibit signaling by the natural ligand). Anotherclass of antagonists may not bind directly to the receptor. Rather, theyact on one or more downstream target molecules of the activated receptoror ion channel, thereby modulating signal transduction of the receptoror ion channel. For example, “antagonists” can be molecules that blockor decrease the signal transduction activity of receptor, e.g., they cancompetitively, noncompetitively, and/or allosterically inhibit signaltransduction from the receptor, whereas “agonists” potentiate, induce orotherwise enhance the signal transduction activity of a receptor. Theterms “receptor activator” and “surrogate ligand” refer to an agonistwhich induces signal transduction from a receptor.

As used herein, “cell surface receptor” refers to molecules that occuron the surface of cells, interact with the extracellular environment,and transmit or transduce the information regarding the environmentintracellularly in a manner that may modulate intracellular secondmessenger activities or transcription of specific promoters, resultingin transcription of specific genes.

The term “compound” as used herein is meant to include, but is notlimited to, peptides, nucleic acids, carbohydrates, small organicmolecules, and natural product extract libraries.

As used herein, “extracellular signals” include a molecule or a changein the environment that is transduced intracellularly via cell surfaceproteins that interact, directly or indirectly, with the signal. Anextracellular signal or effector molecule includes any compound orsubstance that in some manner alters the activity of a cell surfaceprotein. Examples of such signals include, but are not limited to,molecules such as acetylcholine, growth factors and hormones, lipids,sugars and nucleotides that bind to cell surface and/or intracellularreceptors and ion channels and modulate the activity of such receptorsand channels. The term “extracellular signals” also include as yetunidentified substances that modulate the activity of a cellularreceptor, and thereby influence intracellular functions. Suchextracellular signals are potential pharmacological agents that may beused to treat specific diseases by modulating the activity of specificcell surface receptors.

As used herein, “heterologous DNA” or “heterologous nucleic acid”include DNA that does not occur naturally as part of the genome in whichit is present or which is found in a location or locations in the genomethat differs from that in which it occurs in nature. Heterologous DNA isnot endogenous to the cell into which it is introduced, but has beenobtained from another cell. Generally, although not necessarily, suchDNA encodes RNA and proteins that are not normally produced by the cellin which it is expressed. Heterologous DNA may also be referred to asforeign DNA. Any DNA that one of skill in the art would recognize orconsider as heterologous or foreign to the cell in which is expressed isherein encompassed by heterologous DNA. Examples of heterologous DNAinclude, but are not limited to, DNA that encodes test polypeptides,receptors, reporter genes, transcriptional and translational regulatorysequences, selectable or traceable marker proteins, such as a proteinthat confers drug resistance.

The term “indicator gene” generically refers to an expressible (e.g.,able to be transcribed and (optionally) translated) DNA sequence whichis expressed in response to a signal transduction pathway modulated by atarget receptor or ion channel. Exemplary indicator genes includeunmodified endogenous genes of the host cell, modified endogenous genes,or a reporter gene of a heterologous construct, e.g., as part of areporter gene construct.

The term “modulation of a signal transduction activity of a receptorprotein” in its various grammatical forms, as used herein, designatesinduction and/or potentiation, as well as inhibition of one or moresignal transduction pathways downstream of a receptor.

“Orphan receptors” is a designation given to receptors for which nospecific natural ligand has been described and/or for which no functionhas been determined.

The terms “protein”, “polypeptide” and “peptide” are usedinterchangeably herein.

The term “proximate transmembrane segment” is used to describe aminoacids located at a position in the polypeptide in which it influencesthe structure of a transmembrane segment of the receptor or ion channel.In certain embodiments, such positions are within 25 amino acids, andmore preferably within 20 residues, 15 residues, or 10 residues, andmost preferably within 5 residues of the first or last reside of thetransmembrane segment(s).

As used herein, “recombinant cells” include any cells that have beenmodified by the introduction of heterologous DNA. Control cells includecells that are substantially identical to the recombinant cells, but donot express one or more of the proteins encoded by the heterologous DNA,e.g., do not include or express the reporter gene construct, receptor ortest polypeptide.

The terms “recombinant protein”, “heterologous protein” and “exogenousprotein” are used interchangeably throughout the specification and referto a polypeptide which is produced by recombinant DNA techniques,wherein generally, DNA encoding the polypeptide is inserted into asuitable expression vector which is in turn used to transform a hostcell to produce the heterologous protein. That is, the polypeptide isexpressed from a heterologous nucleic acid.

As used herein, a “reporter gene construct” is a nucleic acid thatincludes a “reporter gene” operatively linked to at least onetranscriptional regulatory sequence. Transcription of the reporter geneis controlled by these sequences to which they are linked. The activityof at least one or more of these control sequences is directly orindirectly regulated by the target receptor protein. Exemplarytranscriptional control sequences are promoter sequences. A reportergene is meant to include a promoter-reporter gene construct which isheterologously expressed in a cell.

“Signal transduction” is the processing of physical or chemical signalsfrom the cellular environment through the cell membrane, and may occurthrough one or more of several mechanisms, such asactivation/inactivation of enzymes (such as proteases, or other enzymeswhich may alter phosphorylation patterns or other post-translationalmodifications), activation of ion channels or intracellular ion stores,effector enzyme activation via guanine nucleotide binding proteinintermediates, formation of inositol phosphate, activation orinactivation of adenylyl cyclase, direct activation (or inhibition) of atranscriptional factor and/or activation.

“Small side-chain amino acids” as used herein refers to amino acidshaving small volume side chains, such as Ala, Gly and Ser.

“Medium side-chain amino acids” as used herein refers to amino acidshaving medium volume side chains, such as Asn, Asp, Cys, Pro, Thr andVal.

“Large/bulky side-chain amino acids” as used herein refers to aminoacids having large volume side chains, such as Arg, Glu, Gin, His, Ile,Leu, Lys, Met, Phe, Trp and Tyr.

In certain embodiments of the subject the replacement strategy, thesmall or medium side-chain amino acids (residues being replaced) areeither amino acids with small side-chains (Ala, Gly or Ser) or residueswith small or medium hydrophobic side-chains (Ala, Gly, Pro and Val).Similarly, in a preferred variation to this strategy, the large/bulkyamino acids (replacement residues) include amino acids with medium tolarge, neutral side-chains (Asn, Cys, Gin, His, He, Leu, Met, Phe, Pro,Thr, Trp, Tyr, Val). That is, the replacement is conservative withrespect to charge but not steric considerations. For instance, in oneembodiment, amino acid residues having small side-chains and located inor near a transmembrane domain are replaced with amino acids with mediumto large, neutral side-chains. Preferably, Gly and Ala residues, andoptionally Ser residues, are targeted.

“Statistically significant” as used herein means that quantitativemeasurements of certain activities, either biological or biochemical orboth, are statistically significantly different from one sample to theother. Preferably, an activating mutation will cause an increase inactivity of 50%, more preferably, 2-fold, 5-fold, 10 fold or more when,compared to the wild-type polypeptide. Likewise, an antagonist of anactivated receptor or an ion channel will cause a statisticallysignificant decrease in activity of at least 20%, more preferably 50%,75%, 90%, 95% or even 99%.

III. Exemplary Embodiments

The subject assays provide a means for identifying activating mutationsin transmembrane receptors and ion channels. In general, the variousmutant proteins are expressed in a host cell, the ability of a given setof mutations to activate, the signal transduction activity of the targetreceptor is scored for by up or down-regulation of a detection signal.Second messenger generation via the receptor can be measured in avariety of ways. For example, second messenger generation can bedetected directly. Alternatively, the use of a reporter gene can providea convenient readout. The present invention also provides for a numberof other detection means, such as indicator genes. By whatever meansmeasured, a statistically significant change in the detection signal canbe used to facilitate isolation of those cells from a mixture which havereceived a signal via an activated target receptor, and thus can be usedto isolate the coding sequence for that mutant.

In general the host cells will express recombinant genes encoding thereceptor or ion channel of interest. In certain instances, it may bedesirable to inactivate one or more endogenous genes of the host cells.For example, certain preferred embodiments in which a heterologousreceptor is provided utilize host cells in which the gene for thehomologous receptor has been inactivated. Likewise, other proteinsinvolved in transducing signals from the target receptor can beinactivated, or complemented with an ortholog or paralog from anotherorganism, e.g., yeast G protein subunits can be complemented bymammalian G protein subunits in yeast cells also engineered to express amammalian G protein coupled receptor. Other complementations include,for example, expression of heterologous MAP kinases or ERK kinases, MEKsor MKKs (MAP kinase kinases), MEKKs (MEK kinases), ras, raf, STATs, JAKsand the like.

In certain embodiments the subject assays measure the production ofsecond messengers to determine changes in ligand engagement by thereceptor. In preferred embodiments, changes in GTP hydrolysis, calciummobilization, or phospholipid hydrolysis can be measured.

In other embodiments the assay cells contain an indicator gene. Forinstance, the host cell can harbor a reporter construct containing areporter gene in operative linkage with one or more transcriptionalregulatory elements responsive to the signal transudation activity ofthe receptor protein. Exemplary reporter genes include enzymes, such asluciferase, phosphatase, or p-galactosidase which can produce aspectrometrically active label, e.g., changes in color, fluorescence orluminescence, or a gene product which alters a cellular phenotype, e.g.,cell growth, drug resistance or auxotrophy. In preferred embodiments:the reporter gene encodes a gene product selected from the groupconsisting of chloramphenicol acetyl transferase, beta-galactosidase andsecreted alkaline phosphatase; the reporter gene encodes a gene productwhich confers a growth signal; the reporter gene encodes a gene productfor growth in media containing aminotriazole or canavanine.

In developing the subject assays, it was recognized that a frequentresult of receptor-mediated responses to activating signals was thetranscriptional activation or inactivation of specific genes. Thus,transcription of genes controlled by receptor-responsive transcriptionalelements often reflects the activity of the surface protein by virtue oftransduction of an intracellular signal. To illustrate, with thewild-type receptor, the intracellular signal that is transduced can beinitiated by the specific interaction of the receptor with anextracellular signal, particularly a ligand. This interaction sets inmotion a cascade of intracellular events, the ultimate consequence ofwhich is a rapid and detectable change in the transcription ortranslation of a gene. By selecting transcriptional regulatory sequencesthat are responsive to the transduced intracellular signals andoperatively linking the selected promoters to indicator genes, whosetranscription or translation is readily detectable and measurable, atranscription based assay provides a rapid indication of whether amutation gives rise to an activated receptor or ion channel thatmodulates intracellular transduction.

Indicator gene based assays of this invention measure the end stage ofthe above described cascade of events, e.g., transcriptional modulation.Accordingly, in practicing one embodiment of the assay, a reporter geneconstruct is inserted into the reagent cell in order to generate adetection signal dependent on receptor signaling. Typically, thereporter gene construct will include a reporter gene in operativelinkage with one or more transcriptional regulatory elements responsiveto the signal transduction activity of the target receptor, with thelevel of expression of the reporter gene providing thereceptor-dependent detection signal. As described below, certainendogenous genes can also act as indicator genes, e.g., provide adetectable signal in response to a signal transduction from a receptoror ion channel. In either embodiment, the amount of transcription fromthe indicator gene may be measured using any method known to those ofskill in the art to be suitable. For example, specific mRNA expressionmay be detected using Northern blots or specific protein product may beidentified by a characteristic stain or an intrinsic activity.

In preferred embodiments, the gene product of the indicator gene isdetected by an intrinsic activity associated with that product. Forinstance, the indicator gene may encode a gene product that, byenzymatic activity, gives rise to a detection signal based on, forexample, color, fluorescence, or luminescence.

The amount of expression from the indicator gene is then compared to theamount of expression when the wild-type receptor is expressed. Anystatistically or otherwise significant difference in the amount oftranscription indicates that a given mutation has in some manner alteredthe activity of the specific receptor or ion channel.

In other preferred embodiments, the indicator gene provides a selectionmethod such that cells in which activation of one or more signalpathways of a receptor or ion channel provides a growth advantage to thetreated cell. For example, expression of the indicator gene couldenhance cell viability, relieve a cell nutritional requirement, and/orprovide resistance to a drug.

In other embodiments, changes in intracellular second messenger pathwayscan be detected biochemically rather than biologically. For example,changes in intracellular Ca⁺², phosphorylation states of proteins,activities of intracellular enzymes, and the like can be detected. Stillother detection techniques include microphysiometric devices whichpermit detection of small changes in, e.g., ions or intracellular pH.

Any transfectable cell that can express the desired cell surface proteinin a manner such that the protein functions to intracellularly transducean extracellular signal may be used. Similarly, any cell surface proteinthat is known to those of skill in the art or that may be identified bythose of skill in the art may be used in the assay.

A. Host Cells

Any transfectable cell that can express the desired cell surface proteinin a manner such that the protein functions to intracellularly transducean extracellular signal may be used. Similarly, any cell surface proteinthat is known to those of skill in the art or that may be identified bythose of skill in the art may used in the assay. The cell surfaceprotein may be endogenously expressed on the selected cell or it may beexpressed from cloned DNA.

Suitable host cells for generating the subject assay includeprokaryotes, yeast, or higher eukaryotic cells, including plant andanimal cells, especially mammalian cells. Prokaryotes include gramnegative or gram positive organisms. Examples of suitable mammalian hostcell lines include the COS-7 line of monkey kidney cells (ATCC CRL 1651)(Gluzman et al., Cell 23: 175, 1981), CV-1 cells (ATCC CCL 70), L cells,C127, 3T3, Chinese hamster ovary (CHO), HeLa, HEK-293, SWISS 3T3, andBHK cell lines.

In certain of the embodiments described below, e.g., where pigmentdispersion or aggregation is detected, the host cell is a pigment cellline capable of dispersing or aggregating its pigment in response to anactivate receptor or ion channel. For instance, the host cell can be amelanophore. Cultures of melanophores have been obtained. Continuouslong term cultures of melanophores have been established. See, forexample, Ide (1974) Developmental Biology 41: 380-384; and Daniolos etal. (1990), Pigment Cell Research 3: 38-43.

If yeast cells are used, the yeast may be of any species which arecultivable and in which an exogenous receptor can be made to engage theappropriate signal transduction machinery of the host cell. Suitablespecies include Kluyverei lactis, Schizosaccharomyces pombe, andUstilaqo maydis; Saccharomyces cerevisiae is preferred. Other yeastwhich can be used in practicing the present invention are Neurosporacrassa, Aspergillus niger, Aspergillus nidulans, Pichia pastoris,Candida tropicalis, and Hansenulapolymorpha. The term “yeast”, as usedherein, includes not only yeast in a strictly taxonomic sense, i.e.,unicellular organisms, but also yeast-like multicellular fingi orfilamentous fungi.

The choice of appropriate host cell will also be influenced by thechoice of detection signal. For instance, reporter constructs, asdescribed below, can provide a selectable or screenable trait upontranscriptional activation (or inactivation) in response to a signaltransduction pathway coupled to the target receptor. The reporter genemay be an unmodified gene already in the host cell pathway, such as thegenes responsible for growth arrest in yeast. It may be a host cell genethat has been operably linked to a “receptor-responsive” promoter.Alternatively, it may be a heterologous gene (e.g., a “reporter geneconstruct”) that has been so linked. Suitable genes and promoters arediscussed below. In other embodiments, second messenger generation canbe measured directly in the detection step, such as mobilization ofintracellular calcium or phospholipid metabolism are quantitated. In yetother embodiments indicator genes can be used to detectreceptor-mediated signaling.

Accordingly, it will be understood that to achieve selection orscreening, the host cell must have an appropriate phenotype. Forexample, generating a pheromone-responsive chimeric HIS3 gene in a yeastthat has a wild-type HIS3 gene would frustrate genetic selection. Thus,to achieve nutritional selection, an auxotrophic strain is wanted.

A variety of complementations for use in the subject assay can beconstructed. Indeed, many yeast genetic complementations with mammaliansignal transduction proteins have been described in the art. Forexample, Mosteller et al. (Mol. Cell. Biol. 14: 1104-1112, 1994)demonstrates that human Ras proteins can complement loss of rasmutations in S. cerevisiae. Moreover, Toda et al. (Princess TakamatsuSymp 17: 253-60, 1986) have shown that human ras proteins can complementthe loss of RAS1 and RAS2 proteins in yeast, and hence are functionallyhomologous. Both human and yeast RAS proteins can stimulate themagnesium and guanine nucleotide-dependent adenylate cyclase activitypresent in yeast membranes. Ballester et al. (Cell 59: 681-6, 1989)describe a vector to express the mammalian GAP protein in the yeast 5″.cerevisiae. When expressed in yeast, GAP inhibits the function of thehuman ras protein, and complements the loss of IRA 1. IRAI is a yeastgene that encodes a protein with homology to GAP and acts upstream ofRAS. Mammalian GAP can therefore function in yeast and interact withyeast RAS. Wei et al. (1994) Gene 151: 279-84 describes that a humanRas-specific guanine nucleotide-exchange factor, Cdc25GEF, cancomplement the loss of CDC25 function in S. cerevisiae. Martegani et al.(EMBO J. 11: 2151-7, 1992) describe the cloning by functionalcomplementation of a mouse cDNA encoding a homolog of CDC25, aSaccharomyces cerevisiae RAS activator. Vojtek et al. (J. Cell Sci. 105:777-85, 1993) and Matviw et al. (Mol Cell Biol 12: 5033-40, 1992)describe how a mouse CAP protein, e.g., an adenylyl cyclase associatedprotein associated with ras-mediated signal transduction, cancomplements defects in S. cerevisiae. Papasavvas et al. (Biochem BiophysRes Commun 184: 1378-85, 1992) also suggest that inactivated yeastadenyl cyclase can be complemented by a mammalian adenyl cyclase gene.Hughes et al. (Nature 364: 349-52, 1993) describe the complementation ofbyr1 in fission yeast by mammalian MAP kinase kinase (MEK). Parissentiet al. (Mol Cell Endocrinol 98: 9-16, 1993) describes the reconstitutionof bovine protein kinase C(PKC) in yeast. The Ca²⁺- andphospholipid-dependent Ser/Thr kinase PKC plays important roles in thetransduction of cellular signals in mammalian cells. Marcus et al. (PNAS92: 6180-4, 1995) suggests the complementation of shk1 null mutations inS. pombe by the either the structurally related S. cerevisiae Step 20 ormammalian p65PAK protein kinases.

“Inactivation”, with respect to genes of the host cell, means thatproduction of a functional gene product is prevented or inhibited.Inactivation may be achieved by deletion of the gene, mutation of thepromoter so that expression does not occur, or mutation of the codingsequence so that the gene product is inactive. Inactivation may bepartial or total.

“Complementation”, with respect to genes of the host cell, means that atleast partial function of inactivated gene of the host cell is suppliedby an exogenous nucleic acid. For instance, yeast cells can be“mammalianized”, and even “humanized”, by complementation of receptorand signal transduction proteins with mammalian homologs. To illustrate,inactivation of a yeast Byr2/Stel 1 gene can be complemented byexpression of a human MEKK gene.

B. Generating Mutational Libraries

There are many ways by which the gene library of mutants can begenerated, particularly by the use of degenerate oligonucleotidesequences (in the case of cassette mutagenesis). In one embodiment, theentire coding sequence, or at least that portion which is to bemutagenized, is synthesized, e.g., using automatic DNA synthesizer, andthe synthetic genes or fragments thereof are then ligated into anappropriate gene for expression. The purpose of a degenerate set ofgenes is to provide, in one mixture, all of the sequences encoding thedesired set of potential sequences. The synthesis of degeneratesequences is well known in the art (see for example, Narang, S A (1983)Tetrahedron 39: 3; Itakura et al. (1981) Recombinant DNA, Proc 3rdCleveland Sympos. Macromolecules, ed. AG Walton, Amsterdam: Elsevier pp.273-289; Itakura et al. (1984) Annu. Rev. Biochem. 53: 323; Itakura etal. (1984) Science 198: 1056; Ike et al. (1983) Nucleic Acid Res. 11:477. Such techniques have been employed in the directed evolution ofother proteins (see, for example, Scott et al. (1990) Science 249:386-390; Roberts et al. (1992) PNAS 89: 2429-2433; Devlin et al. (1990)Science 249: 404-406; Cwirla et al. (1990) PNAS 87: 6378-6382; as wellas U.S. Pat. Nos. 5,223,409, 5,198,346, and 5,096,815).

To continue the illustration, the coding sequence for the receptor orion channel is analyzed and residues targeted for mutagenesis areidentified. In an embodiment of a “selective strategy’, only selectedresidues (e.g., all amino acids with small side-chains), and preferablyonly those occurring in the transmembrane domain(s) of the protein, aremutagenized. Alternatively, a more random approach might be takenwherein random (indiscriminate) mutations throughout the transmembranedomain(s) are introduced (such as by PCR-mediated mutagenesis).

Moreover, the mutations which are introduced may be random, e.g., any ofthe 20 amino acids, or selective, e.g., residues which are intended toalter the steric and/or electronic (including charge) nature of theside-chain at the site of mutation. In one embodiment of the selectivestrategy, the residues which are to mutagenized in the TM domains arethose which are characterized as small or medium sized amino acidresidues (e.g., Ala, Gly and Ser for small, and Asn, Asp, Cys, Pro, Thrand Val for medium), and the replacement residues include amino acidswith large side-chains (e.g., Arg, Glu, Gin, His, He, Leu, Lys, Met,Phe, Tip and Tyr). In a preferred variation to this strategy, theresidues being replaced are either amino acids with small side-chains(Ala, Gly or Ser) or residues with small or medium hydrophobicside-chains (Ala, Gly, Pro and Val). In a preferred variation to thisstrategy, the replacement residues include amino acids with medium tolarge, neutral side-chains (Asn, Cys, Gin, His, He, Leu, Met, Phe, Pro,Thr, Trp, Tyr, Val). That is, the replacement is conservative withrespect to charge but not steric considerations. For instance, in oneembodiment, amino acid residues having small side-chains and located inor near a transmembrane domain are replaced with amino acids with mediumto large, neutral side-chains. Preferably, Gly and Ala residues, andoptionally Ser residues, are targeted.

The mutagenic approach can be designed to provide libraries of singlepoint mutations, but will more preferably be representative of thepossible permutations of mutations ranging from single to multiple sitemutations. For instance, where there are three sites to be mutagenizedinto one of 13 different residues, then there are 39 possible singlepoint mutations, 507 possible double mutations and 2197 possible triplemutations—for a total of 2743 permutations.

In preferred embodiments, the receptor library includes at least 10different polypeptides, though more preferably at least 10², 10³, 10⁴,or even 10⁵ different permutations.

C. Expression Systems

Ligating a polynucleotide coding sequence into a gene construct, such asan expression vector, and transforming or transfecting into hosts,either eukaryotic (yeast, avian, insect or mammalian) or prokaryotic(bacterial cells), are standard procedures used in producing otherwell-known proteins, including sequences encoding exogenous receptorsand ion channels. Similar procedures, or modifications thereof, can beemployed to prepare recombinant reagent cells of the present inventionby tissue-culture technology in accord with the subject invention.

In general, it will be desirable that the vector be capable ofreplication in the host cell. It may be a DNA which is integrated intothe host genome, and thereafter is replicated as a part of thechromosomal DNA, or it may be DNA which replicates autonomously, as inthe case of a plasmid. In the latter case, the vector will include anorigin of replication which is functional in the host. In the case of anintegrating vector, the vector may include sequences which facilitateintegration, e.g., sequences homologous to host sequences, or encodingintegrases.

Appropriate cloning and expression vectors for use with bacterial,fungal, yeast, and mammalian cellular hosts are known in the art, andare described in, for example, Powels et al. (Cloning Vectors: ALaboratory Manual, Elsevier, N.Y., 1985). Mammalian expression vectorsmay comprise non-transcribed elements such as an origin of replication,a suitable promoter and enhancer linked to the gene to be expressed, andother 5′ or 3′ flanking nontranscribed sequences, and 5′ or 37nontranslated sequences, such as necessary ribosome binding sites, apoly-adenylation site, splice donor and acceptor sites, andtranscriptional termination sequences.

The preferred mammalian expression vectors contain both prokaryoticsequences, to facilitate the propagation of the vector in bacteria, andone or more eukaryotic transcription units that are expressed ineukaryotic cells. The pcDNAI/amp, pcDNAI/neo, pRc/CMV, pSV2gpt, pSV2neo,pSV2-dhfr, pTk2, pRSVneo, pMSG, pSVT7, pko-neo and pHyg derived vectorsare examples of mammalian expression vectors suitable for transfectionof eukaryotic cells. Some of these vectors are modified with sequencesfrom bacterial plasmids, such as pBR322, to facilitate replication anddrug resistance selection in both prokaryotic and eukaryotic cells.Alternatively, derivatives of viruses such as the bovine papillomavirus(BPV-1), or Epstein-Barr virus (pHEBo, pREP-derived and p205) can beused for transient expression of proteins in eukaryotic cells. Thevarious methods employed in the preparation of the plasmids andtransformation of host organisms are well known in the art. For othersuitable expression systems for both prokaryotic and eukaryotic cells,as well as general recombinant procedures, see Molecular Cloning: ALaboratory Manual, 2nd Ed., ed. by Sambrook, Fritsch and Maniatis (ColdSpring Harbor Laboratory Press: 1989) Chapters 16 and 17.

The transcriptional and translational control sequences in expressionvectors to be used in transforming mammalian cells may be provided byviral sources. For example, commonly used promoters and enhancers arederived from Polyoma, Adenovirus 2, Simian Virus 40 (SV40), and humancytomegalovirus. DNA sequences derived from the SV40 viral genome, forexample, SV40 origin, early and late promoter, enhancer, splice, andpolyadenylation sites may be used to provide the other genetic elementsrequired for expression of a heterologous DNA sequence. The early andlate promoters are particularly useful because both are obtained easilyfrom the virus as a fragment which also contains the SV40 viral originof replication (Fiers et al., Nature 273: 111, 1978). Smaller or largerSV40 fragments may also be used, provided the approximately 250 bpsequence extending from the Hind III site toward the Bgl I site locatedin the viral origin of replication is included. Exemplary vectors can beconstructed as disclosed by Okayama and Berg (Mol. Cell. Biol. 3: 280,1983). A useful system for stable high level expression of mammalianreceptor cDNAs in C127 murine mammary epithelial cells can beconstructed substantially as described by Cosman et al. (Mol. Immunol.23: 935, 1986). Other expression vectors for use in mammalian host cellsare derived from retroviruses.

In other embodiments, the use of viral transfection can provide stablyintegrated copies of the expression construct. In particular, the use ofretro viral, adenoviral or adeno-associated viral vectors iscontemplated as a means for providing a stably transfected cell linewhich expresses an exogenous receptor, and/or a polypeptide library.

A number of vectors exist for the expression of recombinant proteins inyeast. For instance, YEP24, YIP5, YEP51, YEP52, pYES2, and YRP17 arecloning and expression vehicles useful in the introduction of geneticconstructs into S. cerevisiae (see, for example, Broach et al. (1983) inExperimental Manipulation of Gene Expression, ed. M. Inouye AcademicPress, p. 83, incorporated by reference herein). These vectors canreplicate in E. coli due the presence of the pBR322 ori, and in &cerevisiae due to the replication determinant of the yeast 2 micronplasmid. In addition, drug resistance markers such as ampicillin can beused. Moreover, if yeast are used as a host cell, it will be understoodthat the expression of a gene in a yeast cell requires a promoter whichis functional in yeast. Suitable promoters include the promoters formetallothionein, 3-phosphoglycerate kinase (Hitzeman et al., J. Biol.Chem. 255, 2073 (1980) or other glycolytic enzymes (Hess et al., J. Adv.Enzyme Req. 7, 149 (1968); and Holland et al. Biochemistry 17, 4900(1978)), such as enolase, glyceraldehyde-3-phosphate dehydrogenase,hexokinase, pyruvate decarboxylase, phospho-fructokinase,glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvatekinase, triosephosphate isomerase, phospho-glucose isomerase, andglucokinase. Suitable vectors and promoters for use in yeast expressionare further described in R. Hitzeman et al., EPO Publication. No.73,657. Other promoters, which have the additional advantage oftranscription controlled by growth conditions, are the promoter regionsfor alcohol dehydrogenase 2, isocytochrome C, acid phosphatase,degradative enzymes associated with nitrogen metabolism, and theaforementioned metallothionein and glyceraldehyde-3-phosphatedehydrogenase, as well as enzymes responsible for maltose and galactoseutilization. Finally, promoters that are active in only one of the twohaploid mating types may be appropriate in certain circumstances. Amongthese haploid-specific promoters, the pheromone promoters MFa1 and MFa1are of particular interest.

In some instances, it may be desirable to derive the host cell usinginsect cells. In such embodiments, recombinant polypeptides can beexpressed by the use of a baculovirus expression system. Examples ofsuch baculovirus expression systems include pVL-derived vectors (such aspVL1392, pVL1393 and pVL941), pAcUW-derived vectors (such as pAcUWI),and pBlueBac-derived vectors (such as the 13-Gal containing pBlueBacIII).

In constructing suitable expression plasmids, the termination sequencesassociated with these genes, or with other genes which are efficientlyexpressed in the host cell, may also be ligated into the expressionvector 3′ of the heterologous coding sequences to providepolyadenylation and termination of the mRNA.

P. Seven Transmembrane Receptors.

In certain embodiments, the subject method is applied to the discoveryof activating mutations in the 7TM family.

In particular, many different 7TM receptors are known to interact with Gproteins. G protein signaling systems include three components: thereceptor itself, a GTP-binding protein (G protein), and an intracellulartarget protein. The cell membrane acts as a switchboard. Messagesarriving through different receptors can produce a single effect if thereceptors act on the same type of G protein. On the other hand, signalsactivating a single receptor can produce more than one effect if thereceptor acts on different kinds of G proteins, or if the G proteins canact on different effectors.

In their resting state, the G proteins, which consist of alpha (a), beta(P) and gamma (y) subunits, are complexed with the nucleotide guanosinediphosphate (GDP) and are in contact with receptors. When a hormone orother first messenger binds to receptor, the receptor changesconformation and this alters its interaction with the G protein. Thisspurs the a subunit to release GDP, and the more abundant nucleotideguanosine triphosphate (GTP), replaces it, thus activating the Gprotein. The G protein then dissociates to separate the a subunit fromthe still complexed (3 and y subunits. Either the Ga subunit, or the Gpycomplex, depending on the pathway, interacts with an effector. Theeffector (which is often an enzyme) in turn converts an inactiveprecursor molecule into an active “second messenger,” which may diffusethrough the cytoplasm, triggering a metabolic cascade. After a fewseconds, the Ga converts the GTP to GDP, thereby inactivating itself.The inactivated Ga may then reassociate with the GPy complex.

Hundreds, if not thousands, of receptors convey messages throughheterotrimeric G proteins, of which at least 17 distinct forms have beenisolated. Although the greatest variability has been seen in the asubunit, several different P and y structures have been reported. Thereare, additionally, several different G protein-dependent effectors.

Most G protein-coupled receptors are comprised of a single protein chainthat is threaded through the plasma membrane seven times. Such receptorsare often referred to as seven-transmembrane receptors (STRs). More thana hundred different STRs have been found, including many distinctreceptors that bind the same ligand, and there are likely many more STRsawaiting discovery.

In addition, STRs have been identified for which the natural ligands areunknown; these receptors are termed “orphan” G protein-coupledreceptors, as described above. Examples include receptors cloned byNeote et al. (Cell 72: 415, 1993); Kouba et al. (FEBS Lett. 321: 173,1993); Birkenbach et al. (J. Virol. 67: 2209, 1993).

The “exogenous receptors” of the present invention may be any Gprotein-coupled receptor which is exogenous to the cell which is to begenetically engineered for the purpose of the present invention. Thisreceptor may be a plant or animal cell receptor. Screening for bindingto plant cell receptors may be useful in the development of, e.g.,herbicides. In the case of an animal receptor, it may be of invertebrateor vertebrate origin. If an invertebrate receptor, an insect receptor ispreferred, and would facilitate development of insecticides. Thereceptor may also be a vertebrate, more preferably a mammalian, stillmore preferably a human, receptor. The exogenous receptor is alsopreferably a seven transmembrane segment receptor.

Known ligands for G protein coupled receptors include: purines andnucleotides, such as adenosine, cAMP, ATP, UTP, ADP, melatonin and thelike; biogenic amines (and related natural ligands), such as5-hydroxytryptamine, acetylcholine, dopamine, adrenaline, adrenaline,adrenaline, histamine, noradrenaline, noradrenaline, noradrenaline,tyramine/octopamine and other related compounds; peptides such asadrenocorticotrophic hormone (acth), melanocyte stimulating hormone(msh), melanocortins, neurotensin (nt), bombesin and related peptides,endothelins, cholecystokinin, gastrin, neurokinin b (nk3), invertebratetachykinin-like peptides, substance k (nk2), substance p (nk1),neuropeptide y (npy), thyrotropin releasing-factor (trf), bradykinin,angiotensin II, beta-endorphin, c5a anaphalatoxin, calcitonin,chemokines (also called intercrines), corticotrophic releasing factor(erf), dynorphin, endorphin, fmlp and other formylated peptides,follitropin (fsh), fungal mating pheremones, galanin, gastric inhibitorypolypeptide receptor (gip), glucagon-like peptides (glps), glucagon,gonadotropin releasing hormone (gnrh), growth hormone releasinghormone(ghrh), insect diuretic hormone, interleukin-8, leutropin(lh/hcg), met-enkephalin, opioid peptides, oxytocin, parathyroid hormone(pth) and pthrp, pituitary adenylyl cyclase activiating peptide (pacap),secretin, somatostatin, thrombin, thyrotropin (tsh), vasoactiveintestinal peptide (vip), vasopressin, vasotocin; eicosanoids such asip-prostacyclin, pg-prostaglandins, tx-thromboxanes; retinal basedcompounds such as vertebrate 11-cis retinal, invertebrate 11-cis retinaland other related compounds; lipids and lipid-based compounds such ascannabinoids, anandamide, lysophosphatidic acid, platelet activatingfactor, leukotrienes and the like; excitatory amino acids and ions suchas calcium ions and glutamate.

Suitable examples of G-protein coupled receptors include, but are notlimited to, dopaminergic, muscarinic cholinergic, oc-adrenergic,P-adrenergic, opioid (including delta and mu), cannabinoid,serotoninergic, and GABAergic receptors. Preferred receptors include the5HT family of receptors, dopamine receptors, C5a receptor and FPRL-1receptor, cyclo-histidyl-proline-diketopiperazine receptors, melanocytestimulating hormone release inhibiting factor receptor, and receptorsfor neurotensin, thyrotropin releasing hormone, calcitonin,cholecytokinin-A, neurokinin-2, histamine-3, cannabinoid, melanocortin,or adrenomodulin, neuropeptide-Y1 or galanin. Other suitable receptorsare listed in the art. The term “receptor,” as used herein, encompassesboth naturally occurring and mutant receptors.

Many of these G protein-coupled receptors, like the yeast a- anda-factor receptors, contain seven hydrophobic amino acid-rich regionswhich are assumed to lie within the plasma membrane. Specific human Gprotein-coupled STRs for which genes have been isolated and for whichexpression vectors could be constructed include those listed herein andothers known in the art. Thus, the gene would be operably linked to apromoter functional in the cell to be engineered and to a signalsequence that also functions in the cell. For example in the case ofyeast, suitable promoters include STE2, STE3 and GAL10, Suitable signalsequences include those of STE2, STE3 and of other genes which encodeproteins secreted by yeast cells. Preferably, when a yeast cell is used,the codons of the gene would be optimized for expression in yeast. SeeHoekema et al. (Mol. Cell. Biol. 7: 2914-24, 1987); Sharp, et al. (14:5125-43, 1986).

The homology of STRs is discussed in Dohlman et al. (Ann. Rev. Biochem.60: 653-88, 1991). When STRs are compared, a distinct spatial pattern ofhomology is discernible. The transmembrane domains are often the mostsimilar, whereas the N- and C-terminal regions, and the cytoplasmic loopconnecting transmembrane segments V and VI are more divergent.

The functional significance of different STR regions has been studied byintroducing point mutations (both substitutions and deletions) and byconstructing chimeras of different but related STRs. Synthetic peptidescorresponding to individual segments have also been tested for activity.Affinity labeling has been used to identify ligand binding sites.

It is conceivable that when the host cell is a yeast cell, a foreignreceptor will fail to functionally integrate into the yeast membrane,and there interact with the endogenous yeast G protein. More likely,either the receptor will need to be modified (e.g., by replacing itsV-VI loop with that of the yeast STE2 or STE3 receptor), or a compatibleG protein should be provided.

If the wild-type exogenous G protein-coupled receptor cannot be madefunctional in yeast, it may be mutated for this purpose. A comparisonwould be made of the amino acid sequences of the exogenous receptor andof the yeast receptors, and regions of high and low homology identified.Trial mutations would then be made to distinguish regions involved inligand or G protein binding, from those necessary for functionalintegration in the membrane.

The exogenous receptor would then be mutated in the latter region tomore closely resemble the yeast receptor, until functional integrationwas achieved. If this were insufficient to achieve functionality,mutations would next be made in the regions involved in G proteinbinding. Mutations would be made in regions involved in ligand bindingonly as a last resort, and then an effort would be made to preserveligand binding by making conservative substitutions whenever possible.

In the case of an exogenous G-protein coupled receptor, the host cellmust be able to produce a G protein which is activated by the exogenousreceptor, and which can in turn activate the cell's effector(s). The artsuggests that the endogenous host Goc subunit (e.g., GPA) will be oftenbe sufficiently homologous to the “cognate” Goc subunit which isnatively associated with the exogenous receptor for coupling to occur.In some instances, such as expression of mammalian receptors in yeastcells, it will be necessary to genetically engineer the host cell toproduce a foreign Goc subunit which can properly interact with theexogenous receptor. For example, the Goc subunit of the yeast G proteinmay be replaced by the Got subunit natively associated with theexogenous receptor.

Dietzel and Kurjan (Cell 50: 1001, 1987) demonstrated that rat Gasfunctionally coupled to the yeast GPy complex. However, rat Goci2complemented only when substantially overexpressed, while Goco did notcomplement at all. (Kang et al., Mol. Cell. Biol. 10: 2582, 1990).Consequently, with some foreign Goc subunits, it is not feasible tosimply replace the yeast Goc.

If the exogenous G protein coupled receptor is not adequately coupled toyeast GPy by the Goc subunit natively associated with the receptor, theGoc subunit may be modified to improve coupling. These modificationsoften will take the form of mutations which increase the resemblance ofthe Goc subunit to the yeast Goc while decreasing its resemblance to thereceptor-associated Goc. For example, a residue may be changed so as tobecome identical to the corresponding yeast Ga residue, or to at leastbelong to the same exchange group of that residue. After modification,the modified Ga subunit might or might not be “substantially homologous”to the foreign and/or the yeast Ga subunit.

The modifications are preferably concentrated in regions of the Ga whichare likely to be involved in GPy binding. In some embodiments, themodifications will take the form of replacing one or more segments ofthe receptor-associated Ga with the corresponding yeast Ga segment(s),thereby forming a chimeric Ga subunit. (For the purpose of the appendedclaims, the term “segment” refers to three or more consecutive aminoacids.) In other embodiments, point mutations may be sufficient.

This chimeric Ga subunit will interact with the exogenous receptor andthe yeast G(3y complex, thereby permitting signal transduction. Whileuse of the endogenous yeast GPy is preferred, if a foreign or chimericGPy is capable of transducing the signal to the yeast effector, it maybe used instead.

Some aspects of Ga structure are relevant to the design of modified Gasubunits. The amino terminal 66 residues of GPA1 are aligned with thecognate domains of human Gas, Gai2, Gai3, Gal6 and transducin. In theGPA41Ga hybrids, the amino terminal 41 residues (derived from GPA1) areidentical, end with the sequence-LEKQRDKNE- and are underlined foremphasis. All residues following the glutamate (E) residue at position41 are contributed by the human Ga subunits, including the consensusnucleotide binding motif-GxGxxG-. Periods in the sequences indicate gapsthat have been introduced to maximize alignments in this region. Codonbias is mammalian. For alignments of the entire coding regions of GPA1with Gas, Gai, and Gao, Gaq and Gaz, see Dietzel and Kurjan (Cell 50:573, 1987) and Lambright et al. (Nature 369: 621-628, 1994). Additionalsequence information is provided by Mattera et al. (FEBS Lett 206:36-41, 1986), Bray et al. (Proc. Natl. Acad. Sci. USA 83: 8893-8897,1986) and Bray et al. (Proc. Natl. Acad. Sci. USA 84: 5115-5119, 1987).

The gene encoding a G protein homolog of S. cerevisiae was clonedindependently by Dietzel and Kuijan (supra) (SCG1) and by Nakafuku etal. (Proc. Natl. Acad. Sci. 84: 2140-2144, 1987) (GPA1). Sequenceanalysis revealed a high degree of homology between the protein encodedby this gene and mammalian Ga. GPA1 encodes a protein of 472 aminoacids, as compared with approximately 340-350a.a. for most mammalian Gasubunits in four described families, Gas, Gad, Gaq and Gal2/13.Nevertheless, GPA1 shares overall sequence and structural homology withall Ga proteins identified to date. The highest overall homology in GPA1is to the Gai family (48% identity, or 65% with conservativesubstitutions) and the lowest is to GQS (33% identity, or 51% withconservative substitutions) (Nakafuku et al., supra).

The regions of high sequence homology among Ga “subunits are dispersedthroughout their primary sequences, with the regions sharing the highestdegree of homology mapping to sequence that comprises the guaninenucleotide binding/GTPase domain. This domain is structurally similar tothe ap fold of ras proteins and the protein synthesis elongation factorEF-Tu. This highly conserved guanine nucleotide-binding domain consistsof a six-stranded (3 sheet surrounded by a set of five a-helices. It iswithin these p sheets and a helices that the highest degree ofconservation is observed among all Ga proteins, including GPA1. Theleast sequence and structural homology is found in the intervening loopsbetween the p sheets and a helices that define the core GTPase domain.There are a total of four “intervening loops” or “inserts” present inall Ga subunits. In the crystal structures reported to date for the GDP-and GTPyS-liganded forms of bovine rod transducin (Noel et al., Nature366: 654-663, 1993); (Lamnbright et al., Nature 369: 621-628, 1994), theloop residues are found to be outside the core GTPase structure.Functional roles for these loop structures have been established in onlya few instances. A direct role in coupling to phosphodiesterase-y hasbeen demonstrated for residues within inserts 3 and 4 of Gat (Rarick etal., Science 256: 1031-1033, 1992); (Artemyev et al., J. Biol. Chem.267: 25067-25072, 1992), while a “GAP-like” activity has been ascribedto the largely a-helical insert 1 domain of Gas (Markby et al., Science262: 1805-1901, 1993).

While the amino- and carboxy-termini of Ga subunits do not sharestriking homology either at the primary, secondary, or tertiary levels,there are several generalizations that can be made about them. First,the amino termini of Ga subunits have been implicated in the associationof Ga with GPy complexes and in membrane association via N-terminalmyristoylation. In addition, the carboxy-termini have been implicated inthe association of Gapy heterotrimeric complexes with G protein-coupledreceptors (Sullivan et al., Nature 330: 758-760, 1987; West et al., J.Biol. Chem. 260: 14428-14430, 1985; Conklin et al., Nature 363: 274-276,1993). Data in support of these generalizations about the function ofthe N-terminus derive from several sources, including both biochemicaland genetic studies.

As indicated above, there is little if any sequence homology sharedamong the amino termini of Ga subunits. The amino terminal domains of Gasubunits that precede the first p-sheet (containing the sequencemotif-LLLLGAGESG-; see Noel et al., Supra, for the numbering of thestructural elements of Ga subunits) vary in length from 41 amino acids(GPA1) to 31 amino acids (Gat). Most Ga subunits share the consensussequence for the addition of myristic acid at their amino termini(MGxxxS-), although not all Ga subunits that contain this motif havemyristic acid covalently associated with the glycine at position 2(Speigel et al., TIES16: 338-3441, 1991). The role of thispost-translational modification has been inferred from studies in whichthe activity of mutant Ga subunits from which the consensus sequence formyristoylation has been added or deleted has been assayed (Mumby et al.,Proc. Nad. Acad. Sci. USA 87: 728-7321990; Linder et al., J. Biol. Chem.266: 4654-4659, 1991; Gallego et al., Proc. Natl. Acad. Sci. USA 89:9695-9699, 1992). These studies suggest two roles for N-terminalmyristoylation. First, the presence of amino-terminal myristic acid hasin some cases been shown to be required for association of Ga subunitswith the membrane, and second, this modification has been demonstratedto play a role in modulating the association of Ga subunits with GPycomplexes. The role of myristoylation of the GPA1 gene products is, atpresent, unknown.

In other biochemical studies aimed at examining the role of theamino-terminus of Ga in driving the association between Ga and GPysubunits, proteolytically or genetically truncated versions of Gasubunits were assayed for their ability to associate with GPy complexes,bind guanine nucleotides and/or to activate effector molecules. In allcases, Ga subunits with truncated amino termini were deficient in allthree functions (Graf et al., J. Biol. Chem. 267: 24307-24314, 1992;Journot et al., J. Biol. Chem. 265: 9009-9015, 1990; and Neer et al., J.Biol. Chem. 263: 8996-9000, 1988). Slepak et al. (J. Biol. Chem. 268:1414-1423, 1993) reported a mutational analysis of the N-terminal 56a.a. of mammalian Gao expressed in Escherichia coli. Molecules with anapparent reduced ability to interact with exogenously added mammalianGPy were identified in the mutant library. As the authors pointed out,however, the assay used to screen the mutants the extent ofADP-ribosylation of the mutant Ga by pertussis toxin was not acompletely satisfactory probe of interactions between Ga and G(3y.Mutations identified as inhibiting the interaction of the subunits,using this assay, may still permit the complexing of Ga and Gpy whilesterically hindering the ribosylation of Ga by toxin. Genetic studiesexamined the role of amino-terminal determinants of Ga in heterotrimersubunit association have been carried out in both yeast systems usingGPA1-mammalian Ga hybrids (Kang et al., Mol. Cell. Biol. 10: 2582-2590,1990) and in mammalian systems using Gai/Gas hybrids (Russell andJohnson, Mol. Pharmacol. 44: 255-263, 1993). In the former studies, genefusions, composed of yeast GPA1 and mammalian Ga sequences wereconstructed by Kang, et al. {supra) and assayed for their ability tocomplement a gpa1 null phenotype (i.e., constitutive activation of thepheromone response pathway) in S. cerevisiae. Kang, et al. demonstratedthat wild type mammalian Gas, Gai but riot Gao proteins are competent toassociate with yeast Ga and suppress the gpa1 null phenotype, but onlywhen overexpressed. Fusion proteins containing the amino-terminal 330residues of GPA1 sequence linked to 160, 143, or 142 residues of themammalian Gas, Gad and Gao carboxyl-terminal regions, respectively, alsocoupled to the yeast mating response pathway when overexpressed on highcopy plasmids with strong inducible (CUP) or constitutive (PGK)promoters. All three of these hybrid molecules were able to complementthe gpa1 null mutation in a growth arrest assay, and were additionallyable to inhibit a factor responsiveness and mating in tester strains.These last two observations argue that hybrid yeast-mammalian Gasubunits are capable of interacting directly with yeast G(3y, therebydisrupting the normal function of the yeast heterotrimer. Fusionscontaining the amino terminal domain of Gas, Gai or Gao, however, didnot complement the gpa1 null phenotype, indicating a requirement fordeterminants in the amino terminal 330 amino acid residues of GPA1 forassociation and sequestration of yeast GPy complexes. Taken together,these data suggest that determinants in the amino terminal region of Gasubunits determine not only the ability to associate with G(3y subunitsin general, but also with specific Gpy subunits in a species-restrictedmanner.

Hybrid Gai/Gas subunits have been assayed in mammalian expressionsystems. (Russell and Johnson, supra). In these studies, a large numberof chimeric Ga subunits were assayed for an ability to activate adenylylcyclase, and therefore, indirectly, for an ability to interact with(i.e., coupling of Get to GPy=inactive cyclase; uncoupling of Ga fromGPy active cyclase). From these studies a complex picture emerged inwhich determinants in the region between residues 25 and 96 of thehybrids were found to determine the state of activation of these allelesas reflected in their rates of guanine nucleotide exchange and GTPhydrolysis and the extent to which they activated adenylyl cyclase invivo. These data could be interpreted to support the hypothesis thatstructural elements in the region between the amino terminal methionineand the ˜1 sheet identified in the crystal structure of Gat (see Noel etal., supra and Lambright et al., supra) are involved in determining thestate of activity of the heterotrimer by (1) drivingassociation/dissociation between Ga and GPy subunits; (2) drivingGDP/GTP exchange. While there is no direct evidence provided by thesestudies to support the idea that residues in this region of Ga andresidues in GPy subunits contact one another, the data nonethelessprovide a positive indication for the construction of hybrid Ga subunitsthat retain function. There is, however, a negative indicator thatderives from this work in that some hybrid constructs resulted inconstitutive activation of the chimeric proteins (i.e., a loss ofreceptor-dependent stimulation of GPy dissociation and effectoractivation).

In designing Ga subunits capable of transmitting, in yeast, signalsoriginating at mammalian G protein-coupled receptors, two generaldesiderata were recognized. First, the subunits should retain as much ofthe sequence of the native mammalian proteins as possible. Second, thelevel of expression for the heterologous components should approach, asclosely as possible, the level of their endogenous counterparts. Theresults described by King et al. (Science 250: 121-123, 1990) forexpression of the human (32-adrenergic receptor and Gas in yeast, takentogether with negative results obtained by Kang et al. (supra) withfull-length mammalian Ga subunits other than Gas, led us to thefollowing preferences for the development of yeast strains in whichmammalian G protein-coupled receptors could be linked to the pheromoneresponse pathway.

1. Mammalian Ga subunits will be expressed using the native sequence ofeach subunit or, alternatively, as minimal gene fusions with sequencesfrom the amino-terminus of GPA1 replacing the homologous residues fromthe mammalian Ga subunits.

2. Mammalian Ga subunits will be expressed from the GPA1 promoter eitheron low copy plasmids or after integration into the yeast genome as asingle copy gene.

3. Endogenous GPy subunits will be provided by the yeast STE4 and STE18loci.

An alternative to the modification of a mammalian Ga subunit forimproved signal transduction is the modification of the pertinent sitesin the yeast Gp or Gy subunits. The principles discussed already withrespect to Ga subunits apply, mutatis mutandis, to yeast Gp or Gy.

For example, it would not be unreasonable to target the yeast Step 4p Gpsubunit with cassette mutagenesis. Specifically, the region of Step 4pthat encodes several of the dominant negative, signaling-defectivemutations would be an excellent target for cassette mutagenesis whenlooking for coupling of yeast GPy to specific mammalian Ga subunits.

E. Cytokine Receptors

In another embodiment the target receptor is a cytokine receptor.Cytokines are a family of soluble mediators of cell-to-cellcommunication that includes interleukins, interferons, andcolony-stimulating factors. The characteristic features of cytokines liein their functional redundancy and pleiotropy. Most of the cytokinereceptors that constitute distinct superfamilies do not possessintrinsic protein tyrosine kinase domains, yet receptor stimulationusually invokes rapid tyrosine phosphorylation of intracellularproteins, including the receptors themselves. Many members of thecytokine receptor superfamily activate the JAK protein tyrosine kinasefamily, with resultant phosphorylation of the STAT transcriptionalactivator factors. IL-2, IL-7, IL-2 and Interferon y have all been shownto activate JAK kinases (Frank et al., Proc. Natl. Acad. Sci. USA 92:7779-7783, 1995; Scharfe et al., Blood 86: 2077-2085, 1995; Bacon etal., Proc. Natl. Acad. Sci. USA 92: 7307-7311, 1995; and Sakatsume etal., J. Biol Chem 270: 17528-17534, 1995). Events downstream of JAKphosphorylation have also been elucidated. For example, exposure of Tlymphocytes to IL-2 has been shown to lead to the phosphorylation ofsignal transducers and activators of transcription (STAT) proteinsSTAT1a, STAT2P, and STAT3, as well as of two STAT-related proteins, p94and p95. The STAT proteins were found to translocate to the nucleus andto bind to a specific DNA sequence, thus suggesting a mechanism by whichIL-2 may activate specific genes involved in immune cell function (Franket al., supra). Jak3 is associated with the gamma chain of the IL-2,IL-4, and IL-7 cytokine receptors (Fujii et al., Proc. Natl. Acad. Sci.92: 5482-5486, 1995 and Musso et al., J. Exp. Med. 181: 1425-1431,1995). The JAK kinases have also been shown to be activated by numerousligands that signal via cytokine receptors such as, growth hormone anderythropoietin and IL-6 (Kishimoto, Stem cells Suppl 12: 37-44, 1994).

Detection means which may be scored for in the present assay, inaddition to direct detection of second messengers, such as by changes inphosphorylation, includes reporter constructs or indicator genes whichinclude transcriptional regulatory elements responsive to the STATproteins. Described infra.

F. Multisubunit Immune Recognition Receptor (MIRR).

In still another embodiment the receptor is a multisubunit receptor.Receptors can be comprised of multiple proteins referred to as subunits,one category of which is referred to as a multisubunit receptor is amultisubunit immune recognition receptor (MIRR). MIRRs include receptorshaving multiple noncovalently associated subunits and are capable ofinteracting with src-family tyrosine kinases. MIRRs can include, but arenot limited to, B cell antigen receptors, T cell antigen receptors, Fcreceptors and CD22. One example of an MIRR an antigen receptor on thesurface of a B cell. To further illustrate, the MIRR on the surface of aB cell comprises membrane-bound immunoglobulin (mlg) associated with thesubunits Ig-oc and Ig-p or Ig-y, which forms a complex capable ofregulating B cell function when bound by antigen. An antigen receptorcan be functionally linked to an amplifier molecule in a manner suchthat the amplifier molecule is capable of regulating gene transcription.

Src-family tyrosine kinases are enzymes capable of phosphorylatingtyrosine residues of a target molecule. Typically, a src-family tyrosinekinase contains one or more binding domains and a kinase domain. Abinding domain of a src-family tyrosine kinase is capable of binding toa target molecule and a kinase domain is capable of phosphorylating atarget molecule bound to the kinase. Members of the src family oftyrosine kinases are characterized by an N-terminal unique regionfollowed by three regions that contain different degrees of homologyamong all the members of the family. These three regions are referred toas src homology region 1 (SHI), src homology region 2 (SH2) and srchomology region 3 (SH3). Both the SH2 and SH3 domains are believed tohave protein association functions important for the formation of signaltransduction complexes. The amino acid sequence of an N-terminal uniqueregion, varies between each src-family tyrosine kinase. An N-terminalunique region can be at least about the first 40 amino acid residues ofthe N-terminal of a src-family tyrosine kinase.

Syk-family kinases are enzymes capable of phosphorylating tyrosineresidues of a target molecule. Typically, a syk-family kinase containsone or more binding domains and a kinase domain. A binding domain of asyk-family tyrosine kinase is capable of binding to a target moleculeand a kinase domain is capable of phosphorylating a target moleculebound to the kinase. Members of the syk-family of tyrosine kinases arecharacterized by two SH2 domains for protein association function and atyrosine kinase domain.

A primary target molecule is capable of further extending a signaltransduction pathway by modifying a second messenger molecule. Primarytarget molecules can include, but are not limited to,phosphatidylinositol 3-kinase (PI-3K), P21 rasGAPase-activating proteinand associated pi90 and p62 protein, phospholipases such as PLCy1 andPLCy2, MAP kinase, She and VAV. A primary target molecule is capable ofproducing second messenger molecule which is capable of furtheramplifying a transduced signal. Second messenger molecules include, butare not limited to diacylglycerol and inositol 1,4,5-triphosphate (IP3).Second messenger molecules are capable of initiating physiologicalevents which can lead to alterations in gene transcription. For example,production of IP3 can result in release of intracellular calcium, whichcan then lead to activation of calmodulin kinase 11, which can then leadto serine phosphorylation of a DNA binding protein referred to as ETS-1proto-onco-protein. Diacylglycerol is capable of activating the signaltransduction protein, protein kinase C which affects the activity of theAPI DNA binding protein complex. Signal transduction pathways can leadto transcriptional activation of genes such as c-fos, egr-1, and c-myc.

She can be thought of as an adapter molecule. An adapter moleculecomprises a protein that enables two other proteins to form a complex(e.g., a three molecule complex). She protein enables a complex to formwhich includes Grb2 and SOS. She comprises an SH2 domain that incapableof associating with the SH2 domain of Grb2.

Molecules of a signal transduction pathway can associate with oneanother using recognition sequences. Recognition sequences enablespecific binding between two molecules. Recognition sequences can varydepending upon the structure of the molecules that are associating withone another. A molecule can have one or more recognition sequences, andas such can associate with one or more different molecules.

Signal transduction pathways for MIRR complexes are capable ofregulating the biological functions of a cell. Such functions caninclude, but are not limited to the ability of a cell to grow, todifferentiate and to secrete cellular products. MIRR-induced signaltransduction pathways can regulate the biological functions of specifictypes of cells involved in particular responses by an animal, such asimmune responses, inflammatory responses and allergic responses. Cellsinvolved in an immune response can include, for example, B cells, Tcells, macrophages, dendritic cells, natural killer cells and plasmacells. Cells involved in inflammatory responses can include, forexample, basophils, mast cells, eosinophils, neutrophils andmacrophages. Cells involved in allergic responses can include, forexample mast cells, basophils, B cells, T cells and macrophages.

In exemplary embodiments of the subject assay, the detection signal is asecond messengers, such as a phosphorylated src-like protein, includesreporter constructs or indicator genes which include transcriptionalregulatory elements such as serum response element (SRE),12-O-tetradecanoyl-phorbol-13-acetate response element, cyclic AMPresponse element, c-fos promoter, or a CREB-responsive element.

G. Receptor Tyrosine Kinases.

In yet another embodiment, the target receptor is a receptor tyrosinekinase. The receptor tyrosine kinases can be divided into five subgroupson the basis of structural similarities in their extracellular domainsand the organization of the tyrosine kinase catalytic region in theircytoplasmic domains. Sub-groups I (epidermal growth factor (EGF)receptor-like), II (insulin receptor-like) and the eph/eck familycontain cysteine-rich sequences (Hirai et al., Science 238: 1717-1720,1987 and Lindberg and Hunter, Mol. Cell. Biol. 10: 6316-6324, 1990). Thefunctional domains of the kinase region of these three classes ofreceptor tyrosine kinases are encoded as a contiguous sequence (Hanks etal., Science 241: 42-52, 1988). Subgroups III (platelet-derived growthfactor (PDGF) receptor-like) and IV (the fibro-blast growth factor (FGF)receptors) are characterized as having immunoglobulin (Ig)-like folds intheir extracellular domains, as well as having their kinase domainsdivided in two parts by a variable stretch of unrelated amino acids(Yanden and Ullrich, 1988, supra and Hanks et al., 1988, supra).

The family with by far the largest number of known members is the EPHfamily. Since the description of the prototype, the EPH receptor (Hiraiet al., Science 238: 1717-1720, 1987), sequences have been reported forat least ten members of this family, not counting apparently orthologousreceptors found in more than one species. Additional partial sequences,and the rate at which new members are still being reported, suggest thefamily is even larger (Maisonpierre et al., Oncogene 8: 3277-3288, 1993;Andres et al., Oncogene 9: 1461-1467, 1994; Henkemeyer et al., Oncogene9: 1001-1014, 1994; Ruiz et al., Mech Dev 46: 87-100, 1994; Xu et al.,Development 120: 287-299, 1994; Zhou et al., J Neurosci Res 37: 129-143,1994; and references in Tuzi and Gullick, Br J Cancer 69: 417-421,1994). Remarkably, despite the large number of members in the EPHfamily, all of these molecules were identified as orphan receptorswithout known ligands.

The expression patterns determined for some of the EPH family receptorshave implied important roles for these molecules in early vertebratedevelopment. In particular, the timing and pattern of expression of sek,mek4 and some of the other receptors during the phase of gastrulationand early organogenesis has suggested functions for these receptors inthe important cellular interactions involved in patterning the embryo atthis stage (Gilardi-Hebenstreit et al., Oncogene 7: 2499-2506, 1992;Nieto et al., Development 116: 1137-1150, 1992; Henkemeyer et al.,supra; Ruiz et al., supra; and Xu et al., supra). Sek, for example,shows a notable early expression in the two areas of the mouse embryothat show obvious segmentation, namely the somites in the mesoderm andthe rhombomeres of the hindbrain; hence the name sek, for segmentallyexpressed kinase (Gilardi-Hebenstreit et al., supra; Nieto et al.,supra). As in Drosophila, these segmental structures of the mammalianembryo are implicated as important elements in establishing the bodyplan. The observation that Sek expression precedes the appearance ofmorphological segmentation suggests a role for sek in forming thesesegmental structures, or in determining segment-specific cell propertiessuch as lineage compartmentation (Nieto et al., supra). Moreover, EPHreceptors have been implicated, by their pattern of expression, in thedevelopment and maintenance of nearly every tissue in the embryonic andadult body. For instance, EPH receptors have been detected throughoutthe nervous system, the testes, the cartilaginous model of the skeleton,tooth primordia, the infindibular component of the pituitary, variousepithelia tissues, lung, pancreas, liver and kidney tissues.Observations such as this have been indicative of important and uniqueroles for EPH family kinases in development and physiology, but furtherprogress in understanding their action has been severely limited by thelack of information on their ligands.

As used herein, the terms “EPH receptor” or “EPH-type receptor” refer toa class of receptor tyrosine kinases, comprising at least elevenparalogous genes, though many more orthologs exist within this class,e.g. homologs from different species. EPH receptors, in general, are adiscrete group of receptors related by homology and easily recognizable,e.g., they are typically characterized by an extracellular domaincontaining a characteristic spacing of cysteine residues near theN-terminus and two fibronectin type III repeats (Hirai et al., Science238: 1717-1720, 1987; Lindberg et al., Mol Cell Biol 10: 6316-6324,1990; Chan et al., Oncogene 6: 1057-1061, 1991; Maisonpierre et al.,Oncogene 8: 3277-3288, 1993; Andres et al., Oncogene 9: 1461-1467, 1994;Henkemeyer et al., Oncogene 9: 1001-1014, 1994; Ruiz et al., Mech Dev46: 87-100, 1994; Xu et al., Development 120: 287-299, 1994; Zhou etal., J. Neurosci Res 37: 129-143, 1994; and references in Tuzi andGullick, Br J Cancer 69: 417-421, 1994). Exemplary EPH receptors includethe eph, elk, eck, sek, mek4, hek, hek1, eek, erk, tyrol, tyro4, tyros,tyro6, tyrol 1, cek4, cekS, cek6, cek7, cek8, cek9, cek1O, bsk, rtk1,rtk2, rtk3, myk1, myk2, ehk1, ehk2, pagliaccio, htk, erk and nukreceptors. The term “EPH receptor” refers to the membrane form of thereceptor protein, as well as fragments which retain the ability toactivate the receptor pathway.

In exemplary embodiments, the detection signal is provided by detectingphosphorylation of intracellular proteins, e.g., MEKKs, MEKs, or Mapkinases, or by the use of reporter constructs or indicator genes whichinclude transcriptional regulatory elements responsive to c-fos and/orc-jun. Described infra

H. Screening and Selection of Activating Mutants.

When screening for activating mutations, intracellular second messengergeneration can be measured directly. A variety of intracellulareffectors have been identified as being receptor—or ionchannel-regulated, including adenylyl cyclase, cyclic GMP,phosphodiesterases, phosphoinositidases, phosphoinositol kinases, andphospholipases, as well as a variety of ions.

In one embodiment, the GTPase enzymatic activity by G proteins can bemeasured in plasma membrane preparations by determining the breakdown ofy³²P GTP using techniques that are known in the art (For example, seeSignal Transduction: A Practical Approach. G. Milligan, Ed. OxfordUniversity Press, Oxford England). When receptors that modulate cAMP aretested, it will be possible to use standard techniques for cAMPdetection, such as competitive assays which quantitate [3H] cAMP in thepresence of unlabelled cAMP.

Certain receptors and ion channels stimulate the activity ofphospholipase C which stimulates the breakdown of phosphatidylinositol4,5, bisphosphate to 1,4,5-IP3 (which mobilizes intracellular Ca⁺⁺) anddiacylglycerol (DAG) (which activates protein kinase C). Inositol lipidscan be extracted and analyzed using standard lipid extractiontechniques. DAG can also be measured using thin-layer chromatography.Water soluble derivatives of all three inositol lipids (IP1, P2, IP3)can also be quantitated using radiolabelling techniques or HPLC.

The other product of PIP2 breakdown, DAG can also be produced fromphosphatidyl choline. The breakdown of this phospholipid in response toreceptor-mediated signaling can also be measured using a variety ofradiolabelling techniques.

The activation of phospholipase A2 can easily be quantitated using knowntechniques, including, for example, the generation of arachadonate inthe cell.

In various cells, e.g., mammalian cells, specific proteases are inducedor activated in each of several arms of divergent signaling pathways.These may be independently monitored by following their uniqueactivities with substrates specific for each protease.

In the case of certain receptors, and ion channels, it may be desirableto screen for changes in cellular phosphorylation. Such assay formatsmay be useful when the receptor of interest is a receptor kinase orphosphatase. For example, immunoblotting (Lyons and Nelson, Proc. Natl.Acad. Sci. USA 81: 7426-7430, 1984) using anti-phosphotyrosine,anti-phosphoserine or anti-phosphothreonine antibodies. In addition,tests for phosphorylation could be also useful when the receptor itselfmay not be a kinase, but activates protein kinases or phosphatase thatfunction downstream in the signal transduction pathway.

One such cascade is the MAP kinase pathway that appears to mediate bothmitogenic, differentiation and stress responses in different cell types.Stimulation of growth factor receptors results in Ras activationfollowed by the sequential activation of c-Raf, MEK, and p44 and p42 MAPkinases (ERKI and ERK2). Activated MAP kinase then phosphorylates manykey regulatory proteins, including p90RSK and Elk-1 that arephosphorylated when MAP kinase translocates to the nucleus. Homologouspathways exist in mammalian and yeast cells. For instance, an essentialpart of the S. cerevisiae pheromone signaling pathway is comprised of aprotein kinase cascade composed of the products of the STE11, STE7, andFUS3/KSS1 genes (the latter pair are distinct and functionallyredundant). Accordingly, phosphorylation and/or activation of members ofthis kinase cascade can be detected and used to quantitate receptorengagement. Phosphotyrosine specific antibodies are available to measureincreases in tyrosine phosphorylation and phospho-specific antibodiesare commercially available (New England Biolabs, Beverly, Mass.).

In the case of certain receptors and ion channels, it may also bedesirable to screen for changes in other post-translationalmodifications, including, but are not limited to, methylation,acetylation, prenylation, myristoylation, palmitoylation, glycosylation,ubiquitination etc., or any combination thereof. The assay of thesemodifications, including gel electrophoresis and chromatograpgy, arewell-known in the art and thus will not be discussed further.

In yet another embodiment, the signal transduction pathway of thetargeted receptor or ion channel upregulates expression or otherwiseactivates an enzyme that modifies a substrate which can be added to thecell. The signal can be detected by using a detectable substrate, inwhich case lose of the substrate signal is monitored, or alternatively,by using a substrate which produces a detectable product. In preferredembodiments, the conversion of the substrate to product by the activatedenzyme produces a detectable change in optical characteristics of thetest cell, e.g., the substrate and/or product is chromogenically orfluorogenically active. In an illustrative embodiment the signaltransduction pathway causes a change in the activity of a proteolyticenzyme, altering the rate at which it cleaves a substrate peptide (orsimply activates the enzyme towards the substrate). The peptide includesa fluorogenic donor radical, e.g., a fluorescence emitting radical, andan acceptor radical, e.g., an aromatic radical which absorbs thefluorescence energy of the fluorogenic donor radical when the acceptorradical and the fluorogenic donor radical are covalently held in closeproximity. See, for example, U.S. Pat. Nos. 5,527,681, 5,506,115,5,429,766, 5,424,186, and 5,316,691; and Capobianco et al, Anal Biochem204: 96-102, 1992. For example, the substrate peptide has a fluorescencedonor group such as 1-aminobenzoic acid (anthranilic acid or ABZ) oraminomethylcoumarin (AMC) located at one position on the peptide and afluorescence quencher group, such as lucifer yellow, methyl red ornitrobenzo-2-oxo-1,3-diazole (NBD), at a different position near thedistal end of the peptide. A cleavage site for the activated enzyme willbe diposed between each of the sites for the donor and acceptor groups.The intramolecular resonance energy transfer from the fluorescence donormolecule to the quencher will quench the fluorescence of the donormolecule when the two are sufficiently proximate in space, e.g., whenthe peptide is intact. Upon cleavage of the peptide, however, thequencher is separated from the donor group, leaving behind a fluorescentfragment. Thus, activation of the enzyme results in cleavage of thedetection peptide, and dequenching of the fluorescent group.

In a preferred embodiment, the enzyme which cleaves the detectionpeptide is one which is endogenous to the host cell. For example, thebar1 gene of yeast encodes a protease, the expression of which isupregulated by stimulation of the yeast pheromone pathway. Thus, hostcells which have been generated to exploit the pheromone signal pathwayfor detection can be contacted with a suitable detection peptide whichcan be cleaved by bar1 to release a fluorogenic fragment, and the levelof bar1 activity thus determined.

In still other embodiments, the detectable signal can be produced by useof enzymes or chromogenic/fluorescent probes whose activities aredependent on the concentration of a second messenger, e.g., such ascalcium, hydrolysis products of inositol phosphate, cAMP, etc. Forexample, the mobilization of intracellular calcium or the influx ofcalcium from outside the cell can be measured using standard techniques.The choice of the appropriate calcium indicator, fluorescent,bioluminescent, metallochromic, or Câ-sensitive microelectrodes dependson the cell type and the magnitude and time constant of the event understudy (Borle, Environ Health Perspect 84: 45-56, 1990). As an exemplarymethod of Ca^(″1″1″) detection, cells could be loaded with the Ca⁺⁺sensitive fluorescent dye fura-2 or indo-1, using standard methods, andany change in Ca⁺⁺ measured using a fluorometer.

As certain embodiments described above suggest, in addition to directlymeasuring second messenger production, the signal transduction activityof a receptor or ion channel pathway can be measured by detection of atranscription product, e.g., by detecting receptor/channel-mediatedtranscriptional activation (or repression) of a gene(s). Detection ofthe transcription product includes detecting the gene transcript,detecting the product directly (e.g., by immunoassay) or detecting anactivity of the protein (e.g., such as an enzymatic activity orchromogenic/fluorogenic activity); each of which is generally referredto herein as a means for detecting expression of the indicator gene. Theindicator gene may be an unmodified endogenous gene of the host cell, amodified endogenous gene, or a part of a completely heterologousconstruct, e.g., as part of a reporter gene construct.

In one embodiment, the indicator gene is an unmodified endogenous gene.For example, the instant method can rely on detecting thetranscriptional level of such endogenous genes as the c-fos gene (e.g.,in mammalian cells) or the Bar1 or Fus1 genes (e.g., in yeast cells) inresponse to such signal transduction pathways as originating from Gprotein coupled receptors.

In certain instances, it may be desirable to increase the level oftranscriptional activation of the endogenous indicator gene by thesignal pathway in order to, for example, improve the signal-to-noise ofthe test system, or to adjust the level of response to a level suitablefor a particular detection technique. In one embodiment, thetranscriptional activation ability of the signal pathway can beamplified by the overexpression of one or more of the proteins involvedin the intracellular signal cascade, particularly enzymes involved inthe pathway. For example, increased expression of Jun kinases (JNKs) canpotentiate the level of transcriptional activation by a signal in anMEKK/JNKK pathway. Likewise, overexpression of one or more signaltransduction proteins in the yeast pheromone pathway can increase thelevel of Fus1 and/or Bar1 expression. This approach can, of course, alsobe used to potentiate the level of transcription of a heterologousreporter gene as well.

In other embodiments, the sensitivity of an endogenous indicator genecan be enhanced by manipulating the promoter sequence at the naturallocus for the indicator gene. Such manipulation may range from pointmutations to the endogenous regulatory elements to gross replacement ofall or substantial portions of the regulatory elements. In general,manipulation of the genomic sequence for the indicator gene can becarried out using techniques known in the art, including homologousrecombination.

In an exemplary embodiment, the yeast bar1 promoter can, be engineeredby mutagenesis to be more responsive, e.g., to more strongly promotergene transcription, upon stimulation of the yeast pheromone pathway.Thus, the endogenous bar1 promoter of a yeast cell can be replaced,e.g., by homologous recombination, with a bar1 promoter engineered tocause higher levels of expression of bar1 upon pheromone stimulation,and the level of bar1 can be detected, for example, by use of afluorogenic substrate as described above.

In another exemplary embodiment, the promoter (or other transcriptionalregulatory sequences) of the endogenous gene can be “switched out” witha heterologous promoter sequence, e.g., to form a chimeric gene at theindicator gene locus. Again, using such techniques as homologousrecombination, the regulatory sequence can be so altered at the genomiclocus of the indicator gene. For example, the bar1 promoter can bereplaced, at the bar1 locus, with the promoter for the fus1 gene. Thefus1 promoter has a higher responsiveness to stimulation by pheromoneinduction than the bar1 promoter, accordingly can increase thesignal-to-noise and dynamic range of the indicator gene. For otherexemplary embodiments, we note that we have substituted the fus1 andfus2 promoters at other loci, such as for the can1 promoter. Thesestrains will become canavanine sensitive upon expression of the can1gene. A similar approach was used to introduce the fus1 and fus2promoter upstream of the ura3 gene in place of the ura3 promoter, thusconferring uracil prototrophy in a manner dependent on activation of theyeast pheromone signal pathway. Likewise, the fus1 and fus2 promoterregions can be introduced upstream of such genes in order to controltheir expression: gall (conferring deoxygalactose sensitivity orgalactose sensitivity due to the concommitant loss of the Gal 10 gene);[3-D-glucanase (exg1: an easily assayed extracellular enzyme); chitinase(cts1); asparaginase (ast3: hydrolyzes asparagine to ammonia andaspartate); and invertase (suc2); secreted acid phosphatase (pho3 orpho5).

In still another embodiment, a heterologous reporter gene construct canbe used to provide the function of an indicator gene. Reporter geneconstructs are prepared by operatively linking a reporter gene with atleast one transcriptional regulatory element. If only onetranscriptional regulatory element is included it must be a regulatablepromoter. At least one of the selected transcriptional regulatoryelements must be indirectly or directly regulated by the activity of theselected cell-surface receptor whereby activity of the receptor can bemonitored via transcription of the reporter genes.

Many reporter genes and transcriptional regulatory elements are known tothose of skill in the art and others may be identified or synthesized bymethods known to those of skill in the art.

Examples of reporter genes include, but are not limited to CAT(chloramphenicol acetyl transferase) (Alton and Vapnek, Nature 282:864-869, 1979) luciferase, and other enzyme detection systems, such asbeta-Galactosidase; firefly luciferase (deWet et al., Mol. Cell. Biol.7: 725-737, (1987); bacterial luciferase (Engebrecht and Silverman, PNAS1: 4154-4158, 1984; Baldwin et al., Biochemistry 23: 3663-3667, 1984);alkaline phosphatase (Toh et al., Eur. J. Biochem. 182: 231-238, 1989,Hall et al., J. Mol. Appl Gen. 2: 101, 1983), human placental secretedalkaline phosphatase (Cullen and Malim, Methods in Enzymol. 216:362-368, 1992); p-lactamase or GST.

Transcriptional control elements for use in the reporter geneconstructs, or for modifying the genomic locus of an indicator geneinclude, but are not limited to, promoters, enhancers, and repressor andactivator binding sites. Suitable transcriptional regulatory elementsmay be derived from the transcriptional regulatory regions of geneswhose expression is rapidly induced, generally within minutes, ofcontact between the cell surface protein and the effector protein thatmodulates the activity of the cell surface protein. Examples of suchgenes include, but are not limited to, the immediate early genes (see,Sheng et al., Neuron 4: 477-485, 1990), such as c-fos. Immediate earlygenes are genes that are rapidly induced upon binding of a ligand to acell surface protein. The transcriptional control elements that arepreferred for use in the gene constructs include transcriptional controlelements from immediate early genes, elements derived from other genesthat exhibit some or all of the characteristics of the immediate earlygenes, or synthetic elements that are constructed such that genes inoperative linkage therewith exhibit such characteristics. Thecharacteristics of preferred genes from which the transcriptionalcontrol elements are derived include, but are not limited to, low orundetectable expression in quiescent cells, rapid induction at thetranscriptional level within minutes of extracellular simulation,induction that is transient and independent of new protein synthesis,subsequent shut-off of transcription requires new protein synthesis, andmRNAs transcribed from these genes have a short half-life. It is notnecessary for all of these properties to be present.

Other promoters and transcriptional control elements, in addition tothose described above, include the vasoactive intestinal peptide (VIP)gene promoter (cAMP responsive; Fink et al., Proc. Natl. Acad. Sci. 85:6662-6666, 1988); the somatostatin gene promoter (cAMP responsive;Montminy et al., Proc. Natl. Acad. Sci. 83: 6682-6686, 1986; theproenkephalin promoter (responsive to cAMP, nicotinic agonists, andphorbol esters; Comb et al., Nature 323: 353-356, 1986); thephosphoenolpyruvate carboxy-kinase gene promoter (cAMP responsive; Shortet al., J. Biol. Chem. 261: 9721-9726, 1986); the NGFI-A gene promoter(responsive to NGF, cAMP, and serum; Changelian et al., Proc. Natl.Acad. Sci. 86: 377-381, 1989); and others that maybe known to orprepared by those of skill in the art.

In the case of receptors which modulate cyclic AMP, a transcriptionalbased readout can be constructed using the cyclic AMP response elementbinding protein, CREB, which is a transcription factor whose activity isregulated by phosphorylation at a particular serine (SI33). When thisserine residue is phosphorylated, CREB binds to a recognition sequenceknown as a CRE (CAMP Responsive Element) found to the 5′ of promotersknown to be responsive to elevated cAMP levels. Upon binding ofphosphorylated CREB to a CRE, transcription from this promoter isincreased.

Phosphorylation of CREB is seen in response to both increased CAMPlevels and increased intracellular Ca levels. Increased cAMP levelsresult in activation of PKA, which in turn phosphorylates CREB and leadsto binding to CRE and transcriptional activation. Increasedintracellular calcium levels results in activation of calcium/calmodulinresponsive kinase II (CaM kinase II). Phosphorylation of CREB by CaMkinase II is effectively the same as phosphorylation of CREB by PKA, andresults in transcriptional activation of CRE containing promoters.

Therefore, a transcriptionally-based readout can be constructed in cellscontaining a reporter gene whose expression is driven by a basalpromoter containing one or more CRE. Changes in the intracellularconcentration of Ca⁺⁺ (a result of alterations in the activity of thereceptor upon engagement with a ligand) will result in changes in thelevel of expression of the reporter gene if: a) CREB is alsoco-expressed in the cell, and b) either an endogenous or heterologousCaM kinase phosphorylates CREB in response to increases in calcium or ifan exogenously expressed CaM kinase II is present in the same cell. Inother words, stimulation of PLC activity may result in phosphorylationof CREB and increased transcription from the CRE-construct, whileinhibition of PLC activity may result in decreased transcription fromthe CRE-responsive construct.

As described in Bonni et al. (Science 262: 1575-1579, 1993), theobservation that CNTF treatment of SK-N-MC cells leads to the enhancedinteraction of STAT/p91 and STAT related proteins with specific DNAsequences suggested that these proteins might be key regulators ofchanges in gene expression that are triggered by CNTF. Consistent withthis possibility is the finding that DNA sequence elements similar tothe consensus DNA sequence required for STAT/p91 binding are presentupstream of a number of genes previously found to be induced by CNTF(e.g., Human c-fos, Mouse c-fos, Mouse tisl 1, Rat junB, Rat SOD-1, andCNTF). Those authors demonstrated the ability of STAT/p91 binding sitesto confer CNTF responsiveness to a non-responsive reporter gene.Accordingly, a reporter construct for use in the present invention fordetecting signal transduction through STAT proteins, such as fromcytokine receptors, can be generated by using −71 to +109 of the mousec-fos gene fused to the bacterial chloramphenicol acetyltransferase gene(−71fosCAT) or other detectable marker gene. Induction by a cytokinereceptor induces the tyrosine phosphorylation of STAT and STAT-relatedproteins, with subsequent translocation and binding of these proteins tothe STAT-RE. This then leads to activation of transcription of genescontaining this DNA element within their promoters.

In preferred embodiments, the reporter gene is a gene whose expressioncauses a phenotypic change which is screenable or selectable. If thechange is selectable, the phenotypic change creates a difference in thegrowth or survival rate between cells which express the reporter geneand those which do not. If the change is screenable, the phenotypechange creates a difference in some detectable characteristic of thecells, by which the cells which express the marker may be distinguishedfrom those which do not. Selection is preferable to screening in that itcan provide a means for amplifying from the cell culture those cellswhich express an activated receptor or ion channel.

The marker gene is coupled to the receptor signaling pathway so thatexpression of the marker gene is dependent on activation of thereceptor. This coupling may be achieved by operably linking the markergene to a receptor-responsive promoter. The term “receptor-responsivepromoter” indicates a promoter which is regulated by some product of thetarget receptor's signal transduction pathway.

Alternatively, the promoter may be one which is repressed by thereceptor pathway, thereby preventing expression of a product which isdeleterious to the cell. With a receptor repressed promoter, one screensfor activated receptors by linking the promoter to a deleterious gene,and for antagonists, by linking it to a beneficial gene. Repression maybe achieved by operably linking a receptor-induced promoter to a geneencoding mRNA which is antisense to at least a portion of the mRNAencoded by the marker gene (whether in the coding or flanking regions),so as to inhibit translation of that mRNA. Repression may also beobtained by linking a receptor-induced promoter to a gene encoding a DNAbinding repressor protein, and incorporating a suitable operator siteinto the promoter or other suitable region of the marker gene.

In the case of yeast, suitable positively selectable (beneficial) genesinclude the following: URA3, LYS2, HIS3, LEU2, TRP, ADE1, 2, 3, 4, 5, 7,8; ARGI, 3, 4, 5, 6, 8; HIS1, 4, 5; ILV1, 2, 5; THR1, 4; TRP2, 3, 4, 5;LEU1, 4; MET2, 3, 4, 8, 9, 14, 16, 19; URA1, 2, 4, 5,10; H0M3, 6; ASP3;CHOI; ARO 2, 7; CYS3; OLE1; INO1, 2, 4; PRO1, 3. Countless other genesare potential selective markers. The above are involved inwell-characterized biosynthetic pathways. The imidazoleglycerolphosphate dehydratase (IGP dehydratase) gene HIS3 is preferred becauseit is both quite sensitive and can be selected over a broad range ofexpression levels. In the simplest case, the cell is auxotrophic forhistidine (requires histidine for growth) in the absence of activation.Activation leads to synthesis of the enzyme and the cell becomesprototrophic for histidine (does not require histidine). Thus theselection is for growth in the absence of histidine. Since only a fewmolecules per cell of IGP dehydratase are required for histidineprototrophy, the assay is very sensitive.

In a more complex version of the assay, cells can be selected forresistance to aminotriazole (AT), a drug that inhibits the activity ofIGP dehydratase. Cells with low, fixed level of expression of HIS3 aresensitive to the drug, while cells with higher levels are resistant. Theamount of AT can be selected to inhibit cells with a basal level of HIS3expression (whatever that level is) but allow growth of cells with aninduced level of expression. In this case selection is for growth in theabsence of histidine and in the presence of a suitable level of AT.

The marker gene may also be a screenable gene. The screenedcharacteristic may be a change in cell morphology, metabolism or otherscreenable features. Suitable markers include beta-galactosidase (X-gal,C12FDG, Salmon-gal, Magenta-gal (latter two from Biosynth Ag), alkalinephosphatase, horseradish peroxidase, exo-glucanase (product of yeastexb1 gene; nonessential, secreted); luciferase; bacterial greenfluorescent protein; (human placental) secreted alkaline phosphatase(SEAP); and chloramphenicol transferase (CAT). Some of the above can beengineered so that they are secreted (although not P-galactosidase). Apreferred screenable marker gene is beta-galactosidase; yeast cellsexpressing the enzyme convert the colorless substrate X-gal into a bluepigment.

In still another embodiment, the host cell is a pigment cell linecapable of dispersing or aggregating its pigment in response toactivation of a receptor or ion channel. See, for example, U.S. Pat. No.6,051,386. In particular, a pigment disperse assay can be generated byexpression of a recombinant receptor or ion channel in apigment-containing host cell. Activating mutants can be identified bychanges in the rate of pigment dispersion (or aggregation as the casemay be). In preferred embodiments, an imaging system, e.g., a computerguided video system, or even photographs, can be used to identifypigment cells that disperse or aggregate their pigment

The first step in developing a melanophore based methodology forstudying the affects of mutations on receptor activation is to expressthe receptor in the appropriate cells. Several promoters and proceduresfor DNA transfection have been tested for their ability to be used byfrog melanophores to express foreign cDNAs. The tested promoters includeones from CMV (cytomegalovirus), RSV (Rous sarcoma virus), frog heatshock, SV40 early and frog beta-actin while the tested methods ofintroducing DNA into the cells that have been evaluated include calciumphosphate precipitation, DEAF-dextran, lipofection and electroporation.The best combination appears to be the use of a CMV promoter to driveexpression of the coding sequence along with electroporation.

A melanophore assay can be read with, for example, a standard 96 wellplate reader. Although the ability of an activated receptor to inducepigment dispersion or aggregation within melanophores may be easilyrecognized by eye, for high through-put screening, quantitation of thedegree of pigment dispersion, e.g., with a standard 96 well plate, isuseful.

I. Pharmaceutical Preparations of Identified Agents

As set out above, once identified as an activating mutation, the mutantreceptor can then be used to screen for compounds which inhibit thephenotype conferred by the activation of the receptor or ion channel.Thus, the present invention specifically contemplates an assay systemincluding a host cell expressing the mutant receptor or ion channel. Thecell is contacted with one or more test agents, and changes in thesecond messenger generation, expression of transcriptional targets orthe like are detected.

Alternatively, second messengers and transcriptional targets which maybe identified for the first time by the discovery of an activated formof the receptor can subsequently be used as reporters to screen foragonists of the wild-type receptor. Thus, the present inventionspecifically contemplates an assay system including a host cellexpressing the wild-type receptor or ion channel. The cell is contactedwith one or more test agents, and changes in a second messenger orexpression of a transcriptional target identified from the activatedmutant are detected.

After identifying certain test compounds in the subject assay, e.g., aspotential agonists or antagonists of a receptor, the practitioner of thesubject assay will continue to test the efficacy and specificity of theselected compounds both in vitro and in vivo. Whether for subsequent invivo testing, or for administration to an animal as an approved drug,agents identified in the subject assay can be formulated inpharmaceutical preparations for in vivo administration to an animal,preferably a human.

The compounds selected in the subject assay, or a pharmaceuticallyacceptable salt thereof, may accordingly be formulated foradministration with a biologically acceptable medium, such as water,buffered saline, polyol (for example, glycerol, propylene glycol, liquidpolyethylene glycol and the like) or suitable mixtures thereof. Theoptimum concentration of the active ingredient(s) in the chosen mediumcan be determined empirically, according to procedures well known tomedicinal chemists. As used herein, “biologically acceptable medium”includes any and all solvents, dispersion media, and the like which maybe appropriate for the desired route of administration of thepharmaceutical preparation. The use of such media for pharmaceuticallyactive substances is known in the art. Except insofar as anyconventional media or agent is incompatible with the activity of thecompound, its use in the pharmaceutical preparation of the invention iscontemplated. Suitable vehicles and their formulation inclusive of otherproteins are described, for example, in the book Remington'sPharmaceutical Sciences (Remington's Pharmaceutical Sciences. MackPublishing Company, Easton, Pa., USA 1985). These vehicles includeinjectable “deposit formulations”. Based on the above, suchpharmaceutical formulations include, although not exclusively, solutionsor freeze-dried powders of the compound in association with one or morepharmaceutically acceptable vehicles or diluents, and contained inbuffered media at a suitable pH and isosmotic with physiological fluids.In preferred embodiment, the compound can be disposed in a sterilepreparation for topical and/or systemic administration. In the case offreeze-dried preparations, supporting excipients such as, but notexclusively, mannitol or glycine may be used and appropriate bufferedsolutions of the desired volume will be provided so as to obtainadequate isotonic buffered solutions of the desired pH. Similarsolutions may also be used for the pharmaceutical compositions ofcompounds in isotonic solutions of the desired volume and include, butnot exclusively, the use of buffered saline solutions with phosphate orcitrate at suitable concentrations so as to obtain at all times isotonicpharmaceutical preparations of the desired pH, (for example, neutralpH).

1. A method for identifying constitutively activating mutations in areceptor or an ion channel, comprising: (A) providing a library ofcoding sequences for potentially activating mutations of a candidatereceptor or ion channel, which library is generated by replacing codingsequences for small or medium side-chain amino acids with codingsequences for large side-chain amino acids, wherein said small or mediumside-chain amino acids are located in or proximate transmembranesegment(s) of the receptor or ion channel; (B) expressing said libraryin host cells; (C) measuring the activity of the encoded receptor or ionchannels in said host cells; (D) identifying those coding sequence(s)which encoded activated receptors or ion channels.
 2. A method foridentifying a target second messenger or downstream signaling componentof a receptor or ion channel, comprising: (A) identifying an activatingmutation of a receptor or ion channel using the method of claim 1; (B)expressing said activating mutation of a receptor or ion channel in hostcells; and, (C) identifying one or more second messenger molecules ordownstream signaling components whose level is higher or lower or whichis modified as a consequence to expression of said activating mutationof said receptor or ion channel.
 3. The method of claim 2, wherein thereceptor is selected from the group consisting of: a growth factorreceptor, a cytokine receptor, a chemokine receptor, and an multisubunitimmune recognition receptor (MIRR).
 4. The method of claim 2, whereinthe receptor is a multipass transmembrane receptor.
 5. The method ofclaim 4, wherein the receptor is a 7TM receptor selected from the groupconsisting of: a G-protein coupled receptor, a chemoattractant peptidereceptor, a neuropeptide receptor, a light receptor, a neurotransmitterreceptor, and a polypeptide hormone receptor.
 6. The method of claim 2,wherein the receptor is a receptor tyrosine kinase (RTK).
 7. A methodfor identifying an antagonist of an activating mutation of a receptor orion channel, comprising: (A) translationally providing a constitutivelyactive mutant of a receptor or ion channel in an environment, whichactive mutant includes one or more point mutation(s) in or proximate atransmembrane segment(s) of the receptor that replace a small or mediumamino acid residue with a large amino acid residue; (B) contacting thereceptor or ion channel with a test agent; (C) comparing the activity ofthe receptor or ion channel in the presence of the test agent with theactivity of the receptor or ion channel in the absence of the testagent; and, (D) identifying the test agent as an antagonist of theactivated receptor or ion channel if the activity of the receptor or ionchannel in the presence of the test agent is lower than the activity ofthe receptor or ion channel in the absence of the test agent.
 8. Themethod of claim 7, wherein the translationally providing step isperformed in a cell.
 9. The method of claim 8, wherein the cell is aprokaryotic cell.
 10. The method of claim 8, wherein the cell is aeukaryotic cell.
 11. The method of claim 10, wherein the cell isselected from the group consisting of: a mammalian cell, an avian cell,an insect cell, a yeast cell, and a plant cell.
 12. The method of claim10, wherein the cell is a pigment cell capable of dispersing oraggregating its pigment in response to an activated receptor or ionchannel.
 13. The method of claim 7, wherein the test agent is a memberof a library.
 14. The method of claim 13, wherein the library isselected from the group consisting of: a randomly synthesizedpolypeptide library, a semi-randomly synthesized polypeptide library, acDNA encoded polypeptide library, a genomic DNA encoded polypeptidelibrary, a synthetic chemical library, and a natural chemical compoundlibrary.
 15. A method for generating a non-human transgenic animal whichexpresses at least one activating mutant(s) of a receptor or an ionchannel, comprising the steps of: (A) identifying an activating mutantof a receptor or an ion channel using the method of claim 1; and, (B)generating a non-human transgenic animal expressing said activatingmutant.
 16. The method of claim 15, wherein the transgenic animal isselected from the group consisting of: a mammal, an insect, and a yeast.17. A method for identifying a modulator of a receptor or ion channel,comprising: (A) identifying an activating mutation of a receptor or ionchannel using the method of claim 1; (B) identifying one or more secondmessenger molecules or downstream signaling components whose level ishigher or lower or which is modified as a consequence to expression ofsaid activating mutation of said receptor or ion channel; (C) contactingan environment expressing a wild-type receptor or ion channel with atest agent; (D) comparing the level of target second messenger moleculesor down stream signaling components identified in step (B) in thepresence or absence of the test agent; and, (E) determining whether thetest agent increases or decreases the level of the target secondmessenger.
 18. A method of conducting a pharmaceutical business,comprising: (A) by the method of claim 7, identifying one or more agentswhich effects signaling by a cell-surface receptor or ion channel; (B)conducting therapeutic profiling of said identified agent(s), or furtheranalogs thereof, for efficacy and toxicity in animals; and, (C)formulating a pharmaceutical preparation including one or more agentsidentified in step (B) as having an acceptable therapeutic profile. 19.A method of conducting a pharmaceutical business, comprising: (A) by themethod of claim 17, identifying one or more agents which effectssignaling by a cell-surface receptor or ion channel; (B) conductingtherapeutic profiling of said identified agent(s), or further analogsthereof, for efficacy and toxicity in animals; and, (C) formulating apharmaceutical preparation including one or more agents identified instep (B) as having an acceptable therapeutic profile.
 20. The businessmethod of claim 18, further comprising an additional step ofestablishing a distribution system for distributing the pharmaceuticalpreparation for sale.
 21. The business method of claim 18, furtherincluding establishing a sales group for marketing the pharmaceuticalpreparation.
 22. The business method of claim 20, further includingestablishing a sales group for marketing the pharmaceutical preparation.23. A method of conducting a pharmaceutical business, comprising: (A) bythe method of claim 7, identifying one or more agents which effectssignaling by a cell-surface receptor or ion channel; (B) (optionally)conducting therapeutic profiling of the agent for efficacy and toxicityin animals; and, (C) licensing, to a third party, the rights for furtherdrug development of the target agent.
 24. A method of conducting apharmaceutical business, comprising: (A) by the method of claim 17,identifying one or more agents which effects signaling by a cell-surfacereceptor or ion channel; (B) (optionally) conducting therapeuticprofiling of the agent for efficacy and toxicity in animals; and, (C)licensing, to a third party, the rights for further drug development ofthe target agent.